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ABSTRACT 
High-fat diet (HFD) causes renal lipotoxicity that is ameliorated with AMPK activation. 
Although bioactive eicosanoids increase with HFD and are essential in regulation of renal 
disease, their role in the inflammatory response to HFD-induced kidney disease and their 
modulation by AMPK activation remain unexplored. In a mouse model, we explored the 
effects of HFD on eicosanoid synthesis and the role of AMPK activation in ameliorating 
these changes. We used targeted lipidomic profiling with quantitative mass spectrometry 
to determine PUFA and eicosanoid content in kidneys, urine, renal arterial and venous 
circulation. HFD increased phospholipase expression as well as the total and free pro-
inflammatory AA and anti-inflammatory DHA in kidneys. Consistent with the parent PUFA 
levels, the AA-and DHA-derived lipoxygenase (LOX), cytochrome P450, and 
nonenzymatic degradation (NE) metabolites increased in kidneys with HFD, while EPA-
derived LOX and NE metabolites decreased. Conversely, treatment with AICAR, AMPK 
activator, reduced the free AA and DHA content and the DHA-derived metabolites in 
kidney. Interestingly, both kidney and circulating AA, AA metabolites, and EPA-derived 
LOX and NE metabolites are increased with HFD; whereas, DHA metabolites are 
increased in kidney in contrast to their decreased circulating levels with HFD. Together, 
these changes showcase HFD-induced pro- and anti-inflammatory eicosanoid 
dysregulation and highlight the role of AMPK in correcting HFD-induced dysregulated 
eicosanoid pathways. 
. 
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INTRODUCTION 
The prevalence of obesity has continued to rise over the past few decades and was 36.5% 
among US adults between the years 2011 to 2014 (1). Obesity serves as a significant risk 
factor both for the initiation and progression of kidney disease independent of 
hypertension and diabetes (2-4). Excessive intake of calorie-dense lipids leads to organ 
dysfunction both by direct lipotoxicity and inflammation. In fact, the western diet enriched 
in saturated animal fats has been shown to increase albuminuria and cause a faster 
decline in renal function (5). In our previous studies, we established that HFD induced 
kidney disease is characterized by renal hypertrophy, increased albuminuria and elevated 
markers of renal fibrosis and inflammation (6). These HFD-induced markers of 
inflammation, oxidative stress, and fibrosis are reversed by AMP-activated protein kinase 
(AMPK) activation (6, 7).  
 HFD alters the activity of crucial lipid metabolism enzymes Acetyl-CoA carboxylase 
(ACC) and HMG-CoA reductase (HMGCR) contributing to lipid accumulation in the kidney 
(6). Total cholesterol esters and phosphatidylcholine content in the kidney are elevated 
while the fatty acid and triglyceride content is unchanged. Phospholipid accumulation in 
the proximal tubules is associated with lysosomal dysfunction, stagnant autophagic flux, 
mitochondrial dysfunction and inflammasome activation (8). High-fat feeding for long 
periods causes recruitment of macrophages, switch to macrophage pro-inflammatory 
phenotype and increased inflammatory mediators like TNFα, MCP-1, IL-6, COX-2 and IL-
1ȕ (9-12). Diets rich in polyunsaturated fatty acids (PUFAs) are known to change plasma 
lipids, renal phospholipid content, and subsequently PUFA-derived eicosanoid 
inflammation in a rat model of nephrotic syndrome (13). However, the influence of renal 
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eicosanoid synthesis and eicosanoid derived inflammation in HFD induced kidney 
disease is unknown. 
 Eicosanoids are oxylipins derived from arachidonic acid (AA) or related PUFAs and 
are inextricably related to inflammation in the kidney. The primary PUFAs for the n-6 
series and n-3 series, Linoleic acid (LA) and alpha-linolenic acid (ALA) respectively, are 
both derived from the diet. These 18-carbon PUFAs are then metabolized by various 
desaturase and elongase enzymes in a stepwise fashion. However, both LA or ALA are 
acted on by the same enzymes, resulting in a competition between the n-3 and n-6 series 
(14). LA is metabolized through multiple steps to dihomo-Ȗ-linolenic acid (DGLA, 20:3n6) 
and, ultimately, to AA (20:4n6). On the other hand, ALA is metabolized to 
eicosapentaenoic acid (EPA, 20:5 n-3) and subsequently to docosahexaenoic acid (DHA, 
22:6 n-3) (15). These PUFAs are incorporated into membrane phospholipids and 
released by phospholipase A2 (PLA2) under the influence of various stimuli. In 
subsequent reactions, cyclooxygenases (COX), lipoxygenases (LOX), cytochrome P450 
(P450) enzymes act on free PUFAs to form eicosanoids. Some eicosanoids can also be 
formed from PUFAs via non-enzymatic reactions (NE), e.g., isoprostanes.  
 Eicosanoids play an essential role in the regulation of renal physiology and disease 
by modulating renal blood flow, glomerular filtration rate, autoregulation, tubular 
glomerular feedback, excretion of renal water and sodium, and release of renin and 
erythropoietin. HFD feeding causes an increase in circulating eicosanoids. In the kidney, 
these eicosanoids are produced by all different cell types – mesangial cells, renal 
microvessels, and tubular cells. This makes it difficult to pinpoint the actual origin of these 
autacoids without actual profiling of the various compartments. Local production in the 
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kidney will be reflected in the kidney tissue, renal venous compartment, and urine. Recent 
advances in eicosanoid analysis using highly sensitive mass spectrometry (MS) has 
enabled us to profile over 150 different eicosanoid metabolites reliably in all tissues, 
enabling us to systematically profile the changes in the metabolic pathways with HFD and 
AICAR therapy. 
  AMPK is a ubiquitous, heterotrimeric kinase that acts as a cellular energy sensor that 
responds to changes in the intracellular AMP/ATP ratio (16). AICAR (5-aminoimidazole-
4-carboxamide-1-ȕ-D-furanosyl 5’-monophosphate) acts as a specific AMPK agonist 
(17). AMPK activation leads to inhibition of energy-requiring biochemical processes like 
fatty acid synthesis and stimulation of energy-producing biochemical pathways like beta-
oxidation to improve energy efficiency (18). Metabolic stress such as diabetes or obesity 
impair the activity of AMPK, and AMPK activation reduces the initial and sustained 
inflammatory response in the kidney of the HFD-induced kidney disease model (6). Along 
with lipid accumulation, the markers of inflammation were modulated with AICAR use (7). 
AMPK signaling has been shown to influence the secretory PLA2 expression in vascular 
smooth muscle cells (19) and control triglyceride content in adipocytes (20). AMPK 
activation also decreases the formation of 15-LOX metabolites of AA in macrophages 
(21). While AMPK activation is beneficial in lipid and eicosanoid metabolism in other 
tissues, the effect of HFD and AMPK activation on eicosanoid pathways in the kidney is 
unknown. We hypothesized that the high-fat exposure triggers inflammation involving the 
eicosanoid pathway and that eicosanoid production is ameliorated with AMPK activation. 
We used a targeted lipidomic platform to systematically investigate the HFD-associated 
eicosanoid synthesis induced in mice consuming HFD with or without AMPK activation in 
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order to better understand the pathophysiological processes involved in the HFD-induced 
kidney disease.  
 
RESULTS 
HFD increased phospholipase expression and free levels of polyunsaturated fatty acids 
and this action is reversed by AMPK activation. 
 Both cytosolic and secretory PLA2 act on membrane phospholipids to release 
PUFA’s-the precursor of various eicosanoids. Levels of cytosolic phospho-PLA2 (Group 
IV) and secretory PLA2 were both increased with HFD in the kidney, and AICAR treatment 
decreased their levels (Figure 1).  
Targeted lipidomic analysis using MS of kidney tissue revealed unique patterns in the 
total, and free ω3 and ω6 PUFA series that are demonstrated in Figure 2. The total fatty 
acid (FA) (esterified and unesterified FA) and free FA (unesterified, FFA) profiles 
generated from the kidney of mice fed a low fat, standard chow (STD), HFD or HFD with 
the AMPK activator AICAR (HFD+AICAR) are displayed in Supplemental Table 1. The 
total and free EPA are decreased in the kidneys with the HFD (Figure 2A and B, p<0.05) 
and further decreased with AICAR, while both total and free DHA, a n3 fatty acid similar 
to EPA, is increased with HFD and reversed with the use of AICAR (Figure 2C and D, 
p<0.05). While DHA and EPA levels are modulated with HFD, the parent PUFA- ALA 
(total and unesterified) is unchanged. 
 Free and total n6 fatty acid DGLA is decreased in the kidney with HFD but 
unchanged with AICAR (Figure 2E and F). Total and free AA in the kidney are increased 
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by HFD and the free AA decreased with AICAR (Figure 2G and H). Free and total levels 
of LA, the precursor for both DGLA and AA are unchanged by the diet and AICAR in the 
kidney. Delta-6 desaturase (D6D) and delta-5 desaturase (D5D) catalyze desaturations 
at specific positions of FA substrates. Elongases extend the fatty acid carbon chains by 
two carbons. The levels of both desaturases were not different between the three groups 
(Supplementary Figure 1).  
 
HFD dysregulates kidney eicosanoid metabolism that is ameliorated by AMPK activation.  
The eicosanoid metabolites of AA, DHA and EPA are regulated with HFD in the kidney 
(Table 1), and specific metabolites are modulated with AICAR (Figure 3). HFD seems to 
create a clear increase in COX products of AA in the kidney and decrease in COX 
products of EPA. 12- hydroxyl-hexadecatrienoic acid (12HHT) which is a COX / P450 
product is increased with HFD and decreased with AICAR (Figure 3A). P450 products of 
DHA – 16, 17-epoxy-docosapentaenoic acid (16,17-EpDPE) and its product 16-hydroxy-
docosahexaenoic acid (16-HDoHE), and 19,20-epoxy-docosapentaenoic acid (19,20-
EpDPE) and its product 19,20-dihydroxy-docosapentaenoic acid (19,20-DiHDPA) are 
increased with HFD, but only the end products 19,20-DiHDPA and 16-HDoHE are 
decreased with AICAR (Figure 3B and C). LOX products of DHA- hydroxy-
docosahexaenoic acids (HDoHE): 4-HDoHE, 7-HDoHE, 11-HDoHE, and 17-HDoHE and 
its product -15 (t)-protectin D1 (15 (t)-PD1) are increased with HFD (Figure 3D, 3E, and 
3F). NE degradation products of DHA- 8-HDoHE, 10-HDoHE, 13-HDoHE, and 20-HDoHE 
are increased with HFD and decreased with AICAR (Figure 3G and 3H).  
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HFD and AMPK activation alter the urinary eicosanoid profiles.  
HFD induced changes in urine metabolites are illustrated in Table 2 and the metabolites 
that are altered with AICAR in Figure 4.  The overall trend of the kidney continues in the 
urine with predominant increase of COX products of AA in the urine and decrease of COX 
products of EPA. Adrenic acid and its COX metabolite dihomo-prostaglandin PGF2α 
(dihomo-PGF2α) are both increased with HFD in the urine but only dihomo-PGF2α is 
decreased with AICAR (Figure 4A). Dihomo-15- deoxyprostaglandin D2 (dihomo-15d-
PGD2) which is a NE byproduct of another Adrenic acid COX metabolite is decreased 
with HFD and increased with AICAR (Figure 4B).  
 Urine AA (Figure 4C) is increased with HFD and decreased with AICAR which is 
consistent with the trend in the kidney.  Downstream COX metabolites of AA and 
prostaglandin H2 (PGH2) are altered with the HFD and AICAR. P450 metabolite of 
prostaglandin E2 (PGE2) metabolites - 13,14-dihydro-15-keto-prostaglandin E2 (PGEM, 
Figure 4D) is increased with HFD and decreased with AICAR. Another PGH2 metabolite- 
13,14-dihydro-5-keto-prostaglandin F2α (PGFM, Figure 4E) and prostaglandin F2α 
(PGF2α, Figure 4F) both the products of COX are increased with HFD and decreased 
with HFD with AICAR. Prostaglandin D2 (PGD2) metabolite -prostaglandin J2 (PGJ2) is 
increased with HFD, while urinary 13,14-dihydro-15-keto-prostaglandin D2 (dhk-PGD2; 
Figure 4G) both COX metabolites of AA is increased with HFD and decreased with HFD 
with AICAR following the similar pattern in the kidney AA metabolite 5-iso-prostaglandin 
F2α-VI(5-iso-PGF2α-VI) (Figure 4H) which is NE product is increased with HFD and 
decreased with AICAR. Prostaglandin E3 (PGE3) is an EPA metabolite of COX action is 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
9 
 
increased with HFD and decreased with AICAR (Figure 4I). COX metabolites of EPA - 
Thromboxane B3 (TXB3) is decreased with HFD and increased with AICAR (Figure 4J). 
 
HFD and AMPK activation modulate circulating eicosanoid levels 
In order to delineate the origin of the eicosanoids in the kidney, both the renal artery 
(Table 3) and vein (Table 4) were sampled after the mice were fed STD, HFD, and HFD 
with AICAR. The eicosanoid profile of the arterial and venous samples revealed that AA 
and its metabolites- 8,9, epoxy-eicosatrienoic acid (8,9 EET) -a product of P450 were 
both increased with HFD. 5,6- EET and 11,12-EET are increased in the venous circulation 
but not in the arterial circulation. Since these metabolites are also elevated in the kidney, 
this suggested the possible production of the metabolites in the kidney and released into 
the venous circulation. AA COX metabolite 6-keto-prostaglandin F1α is elevated in the 
venous circulation with HFD – this is in line with the elevation of the downstream 
metabolite 6-keto-prostaglandin E1 in the urine.  
 DHA metabolites- 20-HDoHE, 10-HDoHE, and 13-HDoHE -products of NE 
degradation are all decreased in the venous circulation. 11-hydroxy-docosahexaenoic 
acid (11-HDoHE) and 4-HDoHE -products of the LOX pathway while 16-HDoHE the 
product of P450 are all decreased with HFD in the venous circulation. 4-HDoHE and 20-
HDoHE are also decreased with HFD in the arterial circulation.  
 EPA levels are decreased in both the arterial and venous circulation. EPA produces 
hydroxy-eicosapentaenoic acid’s (HEPE) –NE products,18-HEPE, 11-HEPE, and 9-
HEPE were decreased in the arterial and venous circulation. 5-HEPE, 12-HEPE, and 15-
HEPE are produced from their respective LOXs and were decreased with HFD in both 
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the arterial and venous circulation. 15-HEPE is decreased further with AICAR therapy in 
the arterial circulation. P450 metabolite-14(15)-epoxy-eicosatetraenoic acid (14(15)-
EpETE) is decreased with HFD diet in both arterial and venous circulation and further 
with AICAR in the arterial circulation. 
LA metabolites of P450 -9,10-dihydroxy-octadecaenoic acid (9,10-diHOME), 
12,13-dihydroxy-octadecaenoic acid (12,13-diHOME), and 12,13-epoxy-octadecaenoic 
acid (12,13-EpOME) are decreased with HFD and are increased with AICAR in the 
arterial circulation (Figure 5A-C). Venous sampling revealed that 9-hydroxy-octatrienoic 
acid (9-HOTrE) is a product of LOX derived from ALA is decreased with HFD but 
increased with AICAR (Figure 5D). 5-HEPE is LOX metabolites of EPA is decreased with 
HFD and increased with AICAR treatment (Figure 5E).  
 
Specific eicosanoids are altered by AMPK activation  
When taken as a whole, there were significant changes in eicosanoid pathways in arterial 
and venous circulation, urine and kidney compartments (Supplementary Table 2). 
Figure 6 depicts the changes influenced by AICAR therapy on HFD mice. To further 
detect trends in the changes, the highly correlated eicosanoids derived from a parent 
PUFA and acted on by a specific enzymatic pathways were collapsed in to principal 
components and analyzed for trends and statistical significance. Table 5 represents the 
trends in the kidney and urine of these highly correlated metabolites. In the kidney, HFD 
decreased EPA metabolites across all enzymatic pathways, while the COX metabolites 
alone were reversed by AICAR. Meanwhile AA metabolites of urine were mostly elevated 
with HFD, whereas the COX EPA metabolites are decreased with HFD and this is 
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reversed with AICAR therapy. COX metabolites of Adrenic acid are decreased with HFD 
in the urine and this was reversed with AICAR. Table 6 reveals that EPA, DHA and ALA 
metabolites were all decreased with HFD in the arterial and venous blood.  
 
DISCUSSION 
This is the first study to systematically explore the effects of HFD on eicosanoid synthesis 
in the kidney and the role of AMPK activation in ameliorating these changes. We find that 
HFD increases phospholipase A2 expression and activity (through phosphorylation) in 
the kidney that is largely corrected by AMPK activation. HFD increases both the pro-
inflammatory AA and the anti-inflammatory DHA, and their respective downstream 
products in the kidney and urine and these changes are reversed with AICAR therapy. 
However, HFD decreases EPA, DGLA, and LOX and NE metabolites of EPA, while 
AICAR therapy decreases free EPA levels further in the kidney. P450 and NE of LA were 
decreased in the arterial circulation with HFD are returned to pre-HFD levels with AICAR. 
These changes highlight the changes in eicosanoid pathways in the kidney with HFD that 
are ameliorated by AICAR therapy.   
 Obesity and metabolic syndrome patients have demonstrated altered fatty acid 
and eicosanoid metabolism compared to lean subjects. Increased serum DGLA levels 
and low delta-5 desaturase activity was associated with hepatic steatosis over and above 
conventional risk factors in metabolic syndrome subjects (22). Like our HFD mouse 
model, COX, LOX, and P450 metabolites of AA and other PUFA’s are elevated in the 
plasma of obese subjects compared to lean subjects (23). Increased TXA2 can cause 
vasoconstriction and induce transcription of collagen in the glomerular matrix. In contrast, 
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PGI2 counteracts the deleterious TXA2 effects associated with progressive glomerular 
damage by acting as a vasodilator. Decreased urinary PGI2/TXA2 ratio has been 
demonstrated in diabetic humans compared to controls (24). In the Japanese population, 
urinary 8- iso-PGF2α which is a AA metabolite predicts metabolic risks like obesity, 
hypertension, and glucose tolerance (25). Meanwhile, low serum lipoxin A4 levels (AA 
metabolite) are associated with metabolic syndrome risk in Chinese population, similar to 
the elevated kidney levels of lipoxin A4 and its metabolite in our study (26). 
Obesity-induced kidney disease is characterized by glomerular enlargement, 
podocytes loss, and proteinuria eventually leading renal failure (2, 27, 28). In animal 
models, HFD increased kidney weight and glomerular area with Periodic –Acid-Schiff 
(PAS) positive matrix and increased Oil red-O positive vacuolated cells. HFD also caused 
albuminuria, increased glomerular inflammation via the NFκB pathway and increased 
urinary monocyte chemoattractant protein (MCP-1) and hydrogen peroxide (6, 29). 
Increased fat intake increases kidney triglyceride content via increased sterol regulatory 
element proteins -1 and 2 and lipogenesis along with reduced AMPK and increased ACC 
expression and activity in mice (30) (7, 10). Also, HFD decreased renal lipolysis along 
with decreased carnitine palmitoyl acyl-CoA transferase-1 expression (31). Mice fed with 
western diet demonstrated vacuolization of the proximal tubule enriched with multi-
lamellar lysosomal bodies with phospholipids the phenomenon was confirmed with 
human biopsies (32). Human studies have described the accumulation of ectopic lipid in 
obesity-induced kidney disease (4, 33). Mice lacking the innate immune receptor Nlrp3 
did not develop the pathological markers of HFD induced kidney disease indicating 
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pathways regulated by Nlrp3 could control the development of HFD induced renal 
pathology (34). Clearly, HFD causes dysregulation of mainstream lipid metabolism in the 
kidney, but the gateway for many inflammatory mediator’s eicosanoid generation with 
HFD has not been clearly examined. 
“The first and rate-limiting step of eicosanoid synthesis is the liberation of PUFAs from 
their esterified form in the sn-2 position of membrane phospholipids by cytosolic 
phospholipase.  In our study, both the cytosolic (Group IV) and secretory phospholipase 
A2 were elevated with HFD and decreased with AICAR. Cytosolic PLA2 is essential for 
adipocyte differentiation in obesity models (35). Cytosolic PLA2 (Group IV) deficient mice 
are resistant to the hepatic effects of high-fat diet due to the decrease in the production 
of downstream products confirming the crucial role of this enzyme in high induced fat 
disease (36). Cytosolic PLA2 is also central to oxidative signaling in renal epithelial cells 
releasing arachidonic acids and its downstream products (37). Isoenzymes of 
phospholipase A2 are differentially expressed in various tissues in response to 
inflammation; for example, expression of group VII phospholipase A2 gene is increased 
in livers of  Zucker obese rats, while expression of group IVA and VIA phospholipase A2 
was inhibited (38).  Phospholipase A2 isoenzymes also demonstrate substrate selectivity 
to certain forms of phospholipids in membranes and specific PUFA’s (39). Kidney 
desaturases and elongases that are responsible for conversion between the various 
PUFA’s are unaffected by HFD or AMPK activation in our study. However, livers of obese 
Zucker rats demonstrated increased expression of delta-6 desaturase and elongase-6 
(38). Diets in the HFD and STD groups had similar n6 to n3 ratios, and the pattern in the 
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circulation and the kidney do not reflect this ratio. AA is increased in the circulation, 
kidney, and urine with HFD in our study and this is consistent with increased circulating 
PUFA’s demonstrated with HFD feeding in Sprague-Dawley rats (40). In excess nutrient 
states, phospholipase D suppresses AMPK activity through the mammalian/mechanistic 
target of rapamycin (mTOR); in return, AMPK activation decreased phospholipase D 
activity similar to the effect of AMPK activation on other phospholipases in vascular 
smooth muscles, and endothelial cells  (19, 41, 42). Thus, the effect of AMPK activation 
on phospholipases in our study could be responsible for the changes to the PUFA levels 
with AICAR therapy.  
Both COX-1 and COX-2 and their downstream products PGD2, PGE2, and PGI2 
are involved in renal vasodilation. PGE2 is the central prostaglandin synthesized in the 
kidney tubules and mesangial cells- and activation of its receptors cause contraction of 
vascular muscle cells, increased calcium in mesangial cells and inhibits sodium 
reabsorption at the thick ascending limb of the loop of Henle (43). In our study, PGE2 is 
decreased in the kidney with HFD, but its metabolites- PGA2, PGB2, and PGEM are 
increased in the urine with HFD. PGI2 metabolites- 6,15 dk-, dh- PGF1α and 6k-PGE1 are 
increased in the urine with HFD similar to PGD2 metabolites – PGJ2 and dhkPGD2. Urinary 
AA-derived eicosanoids, primarily downstream of COX metabolite-PGH2 were increased 
with HFD and decreased with AICAR therapy. Increased flux in these pathways possibly 
results in decreased bioavailability of the renal vasodilators. In line with our findings, COX-
2 expression was increased in renal cortex, blood vessels and in the urine in obese 
Zucker rats (44). Increased urinary thromboxane B2 (TXB2) and 6-keto PGF1α and 
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decreased PGE2 excretion rates were evident in obese Zucker rats. Similarly, decreased 
urinary PGI2/TXA2 ratio has been demonstrated in diabetic humans as well as in diabetic 
animal models. Rofecoxib, a COX-2 inhibitor, decreases vascular and glomerular damage 
when administered to obese Zucker rats (24). Decreased PGF2α and 8- iso-PGF2α levels 
contribute to the decreased glomerulosclerosis in obese Zucker rats treated with 
rofecoxib. COX-2 inhibition and decreases in 8- iso-PGF2α levels have also been shown 
to ameliorate renal injury associated with hypertensive rats (45). This pattern is also 
reflected in the urinary levels of 8- iso-PGF2α in our mouse model of HFD induced kidney 
disease.  
 Renal P450 epoxidation generates epoxyeicosatrienoic acids (EETs) that are 
metabolized by soluble epoxide hydrolase (sEH) to less active dihydroxyeicosatrienoic 
acids (DHETEs). Decreased renal expression of CYP2C epoxygenase enzymes has 
been observed in diabetes, high fat diet fed insulin resistance rats, and the kidney and 
mesenteric blood vessels of obese Zucker rats (46). Additionally, sEH expression is 
increased in blood vessels of obese rats and could further contribute to the decrease in 
EET bioavailability implicating impaired endothelial dilator responses in obesity and 
diabetes. Cytokines- IL-6 and TNF-α decrease expression of P450 epoxygenase 
enzymes. TNF-α and EET’s act via NFκB pathway causing  elevated MCP-1 levels that 
have been observed in HFD induced kidney disease in mice (6). Obese Zucker rats have 
increased renal vascular CYP4A expression and increased generation of 20-HETE (47). 
However, renal tubular CYP4A expression was decreased in Sprague-Dawley rats on 
HFD (48). AA metabolites -20-HETE, EET, and DHETE are decreased with HFD in the 
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kidney and associated with the diet-induced change in blood pressure and renal function 
of Sprague-Dawley rats (48, 49). In our study, the kidney P450 products of AA- 9-HETE 
and EET’s are increased with HFD just as many of the EET’s are also increased in the 
circulation and urine. Pharmacological inhibition or transgenic deletion of sEH, the 
dominant enzyme in degrading EETs, have been shown to protect mice from various 
adverse effects induced by obesity (50). Thus, protective eicosanoid metabolites of AA-
EET are increased with HFD in the kidney. In HFD fed mice, plasma profiling revealed 
increases in circulating P450 metabolite of LA-EpOME’s (51) which is a different trend to 
the one observed in the arterial circulation of our HFD mice maintained on HFD for a 
longer period. 
 Central adipose tissue in obese Zucker rats shows increased LOX expression 
along with inflammatory markers (52). 5-LOX products induce NF-kappaB expression and 
secretion of inflammatory cytokines like MCP-1, TNF-α, macrophage inflammatory 
protein-1gamma, and IL-6 by the adipose tissue. The 5-LOX pathway plays a major role 
in obesity-induced fatty liver disease (53). In our study, LOX metabolites of AA, AA 
metabolites- 6(R),15 (R)-LXA4 and 6(S)-LXA4 are increased in the kidney with HFD in our 
study, and LXA4 has been shown by our group to attenuate inflammation in HFD related 
kidney disease (10). Similarly, LOX metabolites of DHA – HDoHE were elevated in the 
kidney, whereas LOX metabolites of EPA –HEPE’s were all decreased in the kidney and 
the circulation.  
  Omega 3 fatty acids – DHA and EPA supplementation in ob/ob mice induced 
AMPK phosphorylation and alleviated hepatic steatosis. Omega 3 supplementation is 
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anti-inflammatory, promotes insulin sensitivity and raises n3 fatty acid-derived resolvins 
and protectins (54). Obesity significantly decreased DHA-derived 17-
hydroxydocosahexaenoic acid (17-HDHA, resolvin D1 precursor) and protectin D1 (PD1) 
levels in murine adipose tissue. Notably, 17-HDHA treatment reduced adipose tissue 
expression of inflammatory cytokines, increased adiponectin expression, and improved 
glucose tolerance parallel to insulin sensitivity in obese mice (55). A concentrated 
formulation of n3 PUFAs attenuates albuminuria, renal function, SREBP-1 expression 
and triglyceride levels in the kidney of type 2 diabetic obese db/db mice (56). DHA and 
DHA metabolites in the kidney, the various HDoHE’s, EpDPE and DiHDPA produced by 
P450, LOX and NE in the kidney are all increased with HFD in our study. While the kidney 
and urine DHA metabolites were increased, the circulatory DHA metabolites were 
decreased- suggesting local production in the kidney. With HFD exposure, DHA 
metabolites -15 (t)- PD1 and PDX are both increased in the kidney and urine respectively. 
In our study, n3 EPA metabolites – HEPE’s were all decreased in the kidney, urine, and 
circulation. EPA metabolites - PGH3 and its hydroxyl metabolites were all decreased in 
the circulation with HFD. Downregulation of HEPE’s in our study represents suppression 
of anti-inflammatory signals.  
  AMPK is a nutrient sensor and is inhibited by nutrient excess states. In our prior 
studies, the effects of HFD induced kidney disease were reversed with AMPK activation 
with AICAR therapy. AMPK activation reversed the inflammatory profile, lipid 
accumulation, and low adiponectin levels that were caused by HFD (9, 10, 57). Diet 
reversal alone was unable to improve the renal inflammation and apoptosis in HFD 
induced kidney damage, emphasizing the persistence of renal injury even after eight 
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weeks of dietary control (58). However, AMPK activation with metformin treatment was 
able to reduce the levels of inflammatory and apoptotic markers that remain residual 
despite diet reversal. Also, metformin ameliorated HFD induced glomerular injury, renal 
fatty acid oxidation, and serum adipokine levels  (58-60). Metformin reduces fat content 
by decreasing sterol regulatory element-binding protein 1 (SREBP-1), fatty acid synthase 
(FAS), and acetyl-CoA carboxylase (ACC) expression in the kidney (61). In our study, 
AICAR reversed the upregulation of phospholipase and free PUFA’s. The influence of 
AICAR is evident in reversing the increased hydroxyl DHA metabolites in the kidney and 
COX metabolites of AA in the urine. In the venous circulation, AICAR reverses the 
downregulation of P450 metabolite of LA- 9-HOTrE and LOX metabolite of LA- 5-HEPE. 
HFD has been previously shown to increase leukotoxins- EpOME, while in our study, 
EpOME metabolites are decreased (51). AICAR also reverses the downregulation of 9,10 
DiHOME, 12, 13-DiHOME, and 12,13-EpOME in the arterial circulation in our study. Thus, 
AMPK activation is able to reverse key pathways in eicosanoid metabolism and helps 
ameliorate changes resulting from HFD. 
 In this current study, we demonstrate modulation of PUFA’s and their metabolites after 
HFD as well as AMPK activation in the kidney, but we cannot delineate the origin of the 
various eicosanoids in the circulation and urine which could be from the diet, liver, muscle, 
pancreas and/or gut microbiota. Again, the changes in the eicosanoids might be 
influenced by the upstream action of phospholipases on specific PUFA's whose pattern 
might be reflective of the specific diet; Although both the diets had a similar n6: n3 ratio, 
the specific composition of HFD might have influenced the eicosanoid changes. Also, as 
the influence of AICAR is not restricted to one specific oxygenase or PUFA, its influence 
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on phospholipases might influence its action to follow the pattern of the predominant 
PUFA availability in various compartments. Though we have independently demonstrated 
the effects of HFD on the kidney pathology, lipid, and inflammatory profile, we cannot 
conclusively provide evidence that the eicosanoid changes are the sole cause of the HFD 
induced kidney disease or the reason for the AICAR induced amelioration. Also t 
eicosanoids might have differential changes based on temporal exposure to HFD, and 
this was not conclusively studied in our study. It is also difficult to tease out the source of 
inflammation in such models as both HFD and AICAR therapy, in addition to altering 
inflammation also influence body weight. Other factor to account for is that pharmacologic 
AMPK inhibition might not be complete, and genetic manipulation of AMPK might provide 
a clearer picture. Genetic manipulation of the pathways clearly influenced by AMPK will 
help us study downstream and upstream changes and their interaction with the 
eicosanoid pathways and link them to renal pathology.    
 In summary, in this study using a targeted lipidomic approach, we demonstrate the 
dysregulation of eicosanoid synthesis and metabolism in the kidney with HFD and its 
amelioration with AMPK activation. Our work sheds light on the mechanism behind HFD 
related toxicity and the eicosanoid pathways under the control of AMPK activation in the 
kidney. We also expose the various pro- and anti-inflammatory mechanisms in HFD 
mediated kidney disease that are altered with AMPK activation. Future studies 
manipulating these dysregulated pathways might open therapeutic avenues in the 
management of high fat induced kidney disease. 
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CONCISE METHODS 
Animals. All animal procedures were approved by the Institutional Animal Care and Use 
Committee of University of California, San Diego. Male six week old C57BL/6 mice were 
purchased from Jackson Laboratory (Bar Harbor, ME) were fed a standard diet or a high-
fat diet (STD - 5% fat( PUFA 2.1%; n6 1.9%; n3 0.2%), 24.5% protein, 40% carbohydrate) 
[HFD - 60% of total calories from fat (90% lard + 10% soybean oil, PUFA 16.9%; n6 
15.1%; n3 1.7%), 20% protein, 20% carbohydrate] (D12492, Research Diets, New 
Brunswick, NJ) for 14 weeks. The mice on the STD diet were treated with phosphate 
buffered solution (PBS) and mice on HFD were treated with 5-Aminoimidazole-4-
carboxamide-1-ȕ-D-ribofuranoside (AICAR, 0.5 mg/g body weight, Toronto Chemicals) or 
PBS via intraperitoneal injections for five days a week for a total of 14 weeks (6). Mice 
were placed in metabolic cages for 24-h urine collection before the start of the diets and 
after 14 weeks. Mice were sacrificed after 14 weeks of diet plasma was collected from 
the renal vein, and arterial blood was obtained from direct cardiac puncture. After 
perfusion with PBS, kidneys were snap-frozen in liquid nitrogen for further analysis.  
 
Quantitative total and free fatty acids analysis: Total and free fatty acids were analyzed 
by gas chromatography/mass spectrometry (GC-MS) as previously described (62, 63). 
Briefly, kidney tissue (~10 mg of tissue) was homogenized in 1 mL of PBS containing 
10% methanol. For the analysis of total (esterified and free) fatty acids, kidney 
homogenates (50μL) were spiked with deuterium-labeled fatty acids, acidified with 200 
μL of 0.1 N hydrochloric acid and extracted with 500 μL methanol. Phase separation was 
achieved by the addition of 500 μL of dichloromethane (CH2Cl2), and the organic phase 
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was removed. The extraction with dichloromethane was repeated, and the combined 
extracts were dried under argon gas. For saponification, the dried lipids were 
resuspended in 250 μL methanol and 250 μL 4N potassium hydroxide, vortexed for 30 
sec and incubated at 37C for 1 hr. The lipid hydrolysates were then neutralized with 260 
μL 4N HCl and the free fatty acids were extracted twice with 2 mL isooctane and the 
combined extracts containing the hydrolyzed fatty acids were dried under argon before 
analysis with GC/MS. 
 Free fatty acids were extracted from 50 μL of the kidney tissue homogenates that was 
supplemented with a set of deuterated fatty acids that served as internal standards. The 
extraction was initiated by the addition of 25 μL 1N hydrochloric acid, and 500 μL 
methanol and a bi-phasic solution were formed by the addition of 1 mL isooctane. The 
isooctane phase containing the free fatty acid fraction is removed, the extraction is 
repeated once more, and the combined extracts are dried under argon before analysis 
with the GC/MS. 
 In preparation for GC-MS analysis, the fatty acids- both total fatty acid after 
saponification and free fatty acid extracted from samples and the quantitative standards 
were taken up in 25 μL of 1% diisopropylethylamine in acetonitrile and derivatized with 
25 μL 1% pentafluorobenzyl bromide. The fatty acid esters were analyzed on an Agilent 
6890N gas chromatograph equipped with an Agilent 5973 mass selective detector 
(Agilent, Santa Clara, CA) operated in the negative chemical ionization mode. Fatty acid 
quantitation was achieved by the stable isotope dilution method. 
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Quantitative eicosanoid analysis: Eicosanoids were analyzed by liquid chromatography-
MS (LC-MS), as described before (63, 64). For tissue analysis, eicosanoids were isolated 
from 0.9 mL of kidney homogenate supplemented with a set of internal standards 
consisting of 26 deuterated eicosanoids (Cayman Chemical) by solid phase extraction 
(Strata-X, Phenomenex, Torrance, CA) and eluted into 1 mL methanol. For eicosanoid 
analysis in urine, 600 μL of sample were processed identically. The extracted samples 
were evaporated, reconstituted in 100 μL and a 40 μL aliquot was separated by reverse 
phase liquid chromatography (LC) using a Synergy C18 column (2.1 x 250 mm, 4 μm; 
Phenomenex, Torrance, CA). Eicosanoids were analyzed using a tandem quadrupole 
mass spectrometer (MDS SCIEX 4000 Q Trap; Applied Biosystems, Foster City, CA) via 
scheduled multiple-reaction monitoring (MRM) in the negative ionization mode. 
Eicosanoids were identified in samples by matching the MRM signal and LC retention 
times with those of pure standards. Data analysis was performed using MultiQuant 2.1 
software (Applied Biosystems). Quantitative eicosanoid determination was performed 
using the stable isotope dilution method.  
Immunoblot. Kidney tissue homogenates were electrophoretically separated on NuPAGE 
bis-Tris gels (Life Technologies, USA) and transferred onto nitrocellulose membrane (Life 
Technologies, USA). Antibodies to ELOLV5, cytosolic phospho-phospholipase A2 and 
secretory phospholipase 2 (Abcam, USA), FADS1/FADS2 (Biorbyt, UK) and actin (Sigma, 
USA) were used on the blots. Detection was performed with ECL Plus detection reagents 
(GE Healthcare, USA) after treatment with appropriate secondary antibody treatment. 
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Statistical analysis. Results are presented as mean values ± standard deviation. The 
kidney values were normalized with tissue weight and plasma were normalized to volume. 
Urinary metabolites are all normalized to urine creatinine values. All metabolites were log 
transformed and auto-scaled before undergoing statistical analysis using the 
MetaboAnalyst version 3.0 software, Canada (65). Figures were generated using Graph 
Pad Prism Software version 4.03, California, USA. Difference between data groups was 
evaluated for significance using two-way ANOVA and Fisher's least significant difference 
method (Fisher's LSD) post-hoc tests for multiple comparisons. A p-value less than 0.05 
was defined as statistically significant in the non-mass spectrometry experiments. To 
account for multiple comparisons with a large number of lipid metabolites, false discovery 
rate (FDR, q value) of <0.05 was considered statistically significant. The highly correlated 
metabolites were reduced based on eicosanoids derived from a single enzyme pathway 
from specific parent fatty acid in each tissue compartment were separately aggregated 
into one secondary variable representative of the corresponding pathway using principal 
component (PC) analysis. We have then used the PC explaining the highest variance in 
the variable for further analysis to detect trends using SPSS Version 25, IBM corp (66).  
ACKNOWLEDGMENTS  
The authors would like to acknowledge the support of grants from the Back to Belgium 
Grant from the Belgian Federal Science Policy (AED, BELSPO, Belgium); NHLBI 
K08HL130944 (AVM); DK082841 (KS), DP3DK094532 award (KS); 
R01DK105961(EAD); and P30DK063491 (EAD, OQ); NIGMS R01GM20501(EAD). 
 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
24 
 
COMPETING INTERESTS 
Nothing to declare 
 
AUTHOR CONTRIBUTION  
All authors have approved the final manuscript. Among the authors, AED and KS have 
conceived the experiments; AMA, OQ, and AED have performed the experiments; SP, 
ED, OQ, and KS have overseen the experiments which were performed in their respective 
laboratories; AVM and AED conducted all statistical analysis; KS, AVM, and AED have 
prepared the manuscript. 
 
 
REFERENCES 
1. Ogden, C. L., M. D. Carroll, C. D. Fryar, and K. M. Flegal. 2015. Prevalence of 
Obesity Among Adults and Youth: United States, 2011-2014. NCHS data brief: 1-8. 
2. Mathew, A. V., S. Okada, and K. Sharma. 2011. Obesity related kidney disease. 
Curr Diabetes Rev 7: 41-49. 
3. Bruce, K. D., and C. D. Byrne. 2009. The metabolic syndrome: common origins of 
a multifactorial disorder. Postgraduate medical journal 85: 614-621. 
4. de Vries, A. P., P. Ruggenenti, X. Z. Ruan, M. Praga, J. M. Cruzado, I. M. Bajema, 
V. D. D'Agati, H. J. Lamb, D. Pongrac Barlovic, R. Hojs, M. Abbate, R. Rodriquez, C. E. 
Mogensen, and E. Porrini. 2014. Fatty kidney: emerging role of ectopic lipid in obesity-
related renal disease. Lancet Diabetes Endocrinol 2: 417-426. 
5. Lin, J., T. T. Fung, F. B. Hu, and G. C. Curhan. 2011. Association of dietary 
patterns with albuminuria and kidney function decline in older white women: a subgroup 
analysis from the Nurses' Health Study. Am J Kidney Dis 57: 245-254. 
6. Decleves, A. E., A. V. Mathew, R. Cunard, and K. Sharma. 2011. AMPK mediates 
the initiation of kidney disease induced by a high-fat diet. Journal of the American Society 
of Nephrology : JASN 22: 1846-1855. 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
25 
 
7. Decleves, A. E., Z. Zolkipli, J. Satriano, L. Wang, T. Nakayama, M. Rogac, T. P. 
Le, J. L. Nortier, M. G. Farquhar, R. K. Naviaux, and K. Sharma. 2014. Regulation of lipid 
accumulation by AMK-activated kinase in high fat diet-induced kidney injury. Kidney Int 
85: 611-623. 
8. Yamamoto, T., Y. Takabatake, A. Takahashi, T. Kimura, T. Namba, J. Matsuda, 
S. Minami, J. Y. Kaimori, I. Matsui, T. Matsusaka, F. Niimura, M. Yanagita, and Y. Isaka. 
2017. High-Fat Diet-Induced Lysosomal Dysfunction and Impaired Autophagic Flux 
Contribute to Lipotoxicity in the Kidney. J Am Soc Nephrol 28: 1534-1551. 
9. Borgeson, E., V. Wallenius, G. H. Syed, M. Darshi, J. Lantero Rodriguez, C. 
Biorserud, M. Ragnmark Ek, P. Bjorklund, M. Quiding-Jarbrink, L. Fandriks, C. Godson, 
and K. Sharma. 2017. AICAR ameliorates high-fat diet-associated pathophysiology in 
mouse and ex vivo models, independent of adiponectin. Diabetologia 60: 729-739. 
10. Börgeson, E., A. M. F. Johnson, Y. S. Lee, A. Till, G. H. Syed, S. T. Ali-Shah, P. J. 
Guiry, J. Dalli, R. A. Colas, C. N. Serhan, K. Sharma, and C. Godson. 2015. Lipoxin A(4) 
attenuates obesity-induced adipose inflammation and associated liver and kidney 
disease. Cell metabolism 22: 125-137. 
11. van der Heijden, R. A., J. Bijzet, W. C. Meijers, G. K. Yakala, R. Kleemann, T. Q. 
Nguyen, R. A. de Boer, C. G. Schalkwijk, B. P. C. Hazenberg, U. J. F. Tietge, and P. 
Heeringa. 2015. Obesity-induced chronic inflammation in high fat diet challenged 
C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. 
Scientific reports 5: 16474. 
12. Altunkaynak, M. E., E. Özbek, B. Z. Altunkaynak, İ. Can, D. Unal, and B. Unal. 
2008. The effects of high-fat diet on the renal structure and morphometric parametric of 
kidneys in rats. Journal of Anatomy 212: 845-852. 
13. Barcelli, U. O., D. C. Beach, B. Thompson, M. Weiss, and V. E. Pollak. 1988. A 
diet containing n−γ and n−6 fatty acids favorably alters the renal phospholipids, 
eicosanoid synthesis and plasma lipids in nephrotic rats. Lipids 23: 1059-1063. 
14. Nakamura, M. T., and T. Y. Nara. 2003. Essential fatty acid synthesis and its 
regulation in mammals. Prostaglandins, leukotrienes, and essential fatty acids 68: 145-
150. 
15. Schmitz, G., and J. Ecker. 2008. The opposing effects of n-3 and n-6 fatty acids. 
Prog Lipid Res 47: 147-155. 
16. Carling, D. 2004. The AMP-activated protein kinase cascade--a unifying system 
for energy control. Trends in biochemical sciences 29: 18-24. 
17. Corton, J. M., J. G. Gillespie, S. A. Hawley, and D. G. Hardie. 1995. 5-
aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-
activated protein kinase in intact cells? Eur J Biochem 229: 558-565. 
18. Hardie, D. G., S. A. Hawley, and J. W. Scott. 2006. AMP-activated protein kinase-
-development of the energy sensor concept. J Physiol 574: 7-15. 
19. El Hadri, K., C. Denoyelle, L. Ravaux, B. Viollet, M. Foretz, B. Friguet, M. Rouis, 
and M. Raymondjean. 2015. AMPK Signaling Involvement for the Repression of the IL-
1ȕ-Induced Group IIA Secretory Phospholipase A2 Expression in VSMCs. PLOS ONE 
10: e0132498. 
20. Jiang, S., H. Chen, Z. Wang, J. J. Riethoven, Y. Xia, J. Miner, and M. Fromm. 
2011. Activated AMPK and prostaglandins are involved in the response to conjugated 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
26 
 
linoleic acid and are sufficient to cause lipid reductions in adipocytes. The Journal of 
nutritional biochemistry 22: 656-664. 
21. Namgaladze, D., R. G. Snodgrass, C. Angioni, N. Grossmann, N. Dehne, G. 
Geisslinger, and B. Brüne. 2015. AMP-activated Protein Kinase Suppresses 
Arachidonate 15-Lipoxygenase Expression in Interleukin 4-polarized Human 
Macrophages. Journal of Biological Chemistry 290: 24484-24494. 
22. Matsuda, M., T. Kawamoto, and R. Tamura. 2017. Predictive value of serum 
dihomo-gamma-linolenic acid level and estimated Delta-5 desaturase activity in patients 
with hepatic steatosis. Obes Res Clin Pract 11: 34-43. 
23. Li, S., Q. Chu, J. Ma, Y. Sun, T. Tao, R. Huang, Y. Liao, J. Yue, J. Zheng, L. Wang, 
X. Xue, M. Zhu, X. Kang, H. Yin, and W. Liu. 2017. Discovery of Novel Lipid Profiles in 
PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production? J Clin 
Endocrinol Metab 102: 810-821. 
24. Dey, A., C. Maric, W. H. Kaesemeyer, C. Z. Zaharis, J. Stewart, J. S. Pollock, and 
J. D. Imig. 2004. Rofecoxib decreases renal injury in obese Zucker rats. Clin Sci (Lond) 
107: 561-570. 
25. Mure, K., N. Yoshimura, M. Hashimoto, S. Muraki, H. Oka, S. Tanaka, H. 
Kawaguchi, K. Nakamura, T. Akune, and T. Takeshita. 2015. Urinary 8-iso-prostaglandin 
F2alpha as a marker of metabolic risks in the general Japanese population: The ROAD 
study. Obesity (Silver Spring) 23: 1517-1524. 
26. Yu, D., Z. Xu, X. Yin, F. Zheng, X. Lin, Q. Pan, and H. Li. 2015. Inverse 
Relationship between Serum Lipoxin A4 Level and the Risk of Metabolic Syndrome in a 
Middle-Aged Chinese Population. PLoS One 10: e0142848. 
27. Chen, H. M., Z. H. Liu, C. H. Zeng, S. J. Li, Q. W. Wang, and L. S. Li. 2006. 
Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis 48: 
772-779. 
28. Kambham, N., G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D'Agati. 2001. 
Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498-1509. 
29. Mima, A., T. Yasuzawa, G. L. King, and S. Ueshima. 2018. Obesity-associated 
glomerular inflammation increases albuminuria without renal histological changes. FEBS 
open bio 8: 664-670. 
30. Jiang, T., Z. Wang, G. Proctor, S. Moskowitz, S. E. Liebman, T. Rogers, M. S. 
Lucia, J. Li, and M. Levi. 2005. Diet-induced obesity in C57BL/6J mice causes increased 
renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding 
protein-1c-dependent pathway. The Journal of biological chemistry 280: 32317-32325. 
31. Kume, S., T. Uzu, S. Araki, T. Sugimoto, K. Isshiki, M. Chin-Kanasaki, M. 
Sakaguchi, N. Kubota, Y. Terauchi, T. Kadowaki, M. Haneda, A. Kashiwagi, and D. Koya. 
2007. Role of altered renal lipid metabolism in the development of renal injury induced by 
a high-fat diet. Journal of the American Society of Nephrology : JASN 18: 2715-2723. 
32. Rampanelli, E., P. Ochodnicky, J. P. Vissers, L. M. Butter, N. Claessen, A. 
Calcagni, L. Kors, L. A. Gethings, S. J. Bakker, M. H. de Borst, G. J. Navis, G. Liebisch, 
D. Speijer, M. A. van den Bergh Weerman, B. Jung, J. Aten, E. Steenbergen, G. Schmitz, 
A. Ballabio, S. Florquin, J. M. Aerts, and J. C. Leemans. 2018. Excessive dietary lipid 
intake provokes an acquired form of lysosomal lipid storage disease in the kidney. J 
Pathol 246: 470-484. 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
27 
 
33. D'Agati, V. D., A. Chagnac, A. P. de Vries, M. Levi, E. Porrini, M. Herman-
Edelstein, and M. Praga. 2016. Obesity-related glomerulopathy: clinical and pathologic 
characteristics and pathogenesis. Nat Rev Nephrol 12: 453-471. 
34. Bakker, P. J., L. M. Butter, L. Kors, G. J. Teske, J. Aten, F. S. Sutterwala, S. 
Florquin, and J. C. Leemans. 2014. Nlrp3 is a key modulator of diet-induced nephropathy 
and renal cholesterol accumulation. Kidney Int 85: 1112-1122. 
35. Pena, L., C. Meana, A. M. Astudillo, G. Lorden, M. Valdearcos, H. Sato, M. 
Murakami, J. Balsinde, and M. A. Balboa. 2016. Critical role for cytosolic group IVA 
phospholipase A2 in early adipocyte differentiation and obesity. Biochim Biophys Acta 
1861: 1083-1095. 
36. Ii, H., N. Yokoyama, S. Yoshida, K. Tsutsumi, S. Hatakeyama, T. Sato, K. Ishihara, 
and S. Akiba. 2009. Alleviation of high-fat diet-induced fatty liver damage in group IVA 
phospholipase A2-knockout mice. PLoS One 4: e8089. 
37. Cui, X.-L., Y. Ding, L. D. Alexander, C. Bao, O. K. Al-Khalili, M. Simonson, D. C. 
Eaton, and J. G. Douglas. 2006. Oxidative signaling in renal epithelium: Critical role of 
cytosolic phospholipase A2 and p38(SAPK). Free radical biology & medicine 41: 213-
221. 
38. Fevre, C., S. Bellenger, A. S. Pierre, M. Minville, J. Bellenger, J. Gresti, M. 
Rialland, M. Narce, and C. Tessier. 2011. The metabolic cascade leading to eicosanoid 
precursors--desaturases, elongases, and phospholipases A2--is altered in Zucker fatty 
rats. Biochim Biophys Acta 1811: 409-417. 
39. Diez, E., F. H. Chilton, G. Stroup, R. J. Mayer, J. D. Winkler, and A. N. Fonteh. 
1994. Fatty acid and phospholipid selectivity of different phospholipase A2 enzymes 
studied by using a mammalian membrane as substrate. Biochem J 301 ( Pt 3): 721-726. 
40. Liu, T.-W., T. D. Heden, E. M. Morris, K. L. Fritsche, V. J. Vieira-Potter, and J. P. 
Thyfault. 2015. High-fat diet alters serum fatty acid profiles in obesity prone rats: 
implications for in-vitro studies. Lipids 50: 997-1008. 
41. Mukhopadhyay, S., M. Saqcena, A. Chatterjee, A. Garcia, M. A. Frias, and D. A. 
Foster. 2015. Reciprocal regulation of AMP-activated protein kinase and phospholipase 
D. The Journal of biological chemistry 290: 6986-6993. 
42. Yang, L., H.-L. Cong, S.-F. Wang, and T. Liu. 2017. AMP-activated protein kinase 
mediates the effects of lipoprotein-associated phospholipase A2 on endothelial 
dysfunction in atherosclerosis. Experimental and therapeutic medicine 13: 1622-1629. 
43. Breyer, M. D., Y. Zhang, Y. F. Guan, C. M. Hao, R. L. Hebert, and R. M. Breyer. 
1998. Regulation of renal function by prostaglandin E receptors. Kidney Int Suppl 67: 
S88-94. 
44. Dey, A., R. S. Williams, D. M. Pollock, D. W. Stepp, J. W. Newman, B. D. 
Hammock, and J. D. Imig. 2004. Altered Kidney CYP2C and Cyclooxygenase-2 Levels 
Are Associated with Obesity-Related Albuminuria. Obesity Research 12: 1278-1289. 
45. Tomida, T., Y. Numaguchi, Y. Nishimoto, M. Tsuzuki, Y. Hayashi, H. Imai, H. 
Matsui, and K. Okumura. 2003. Inhibition of COX-2 prevents hypertension and proteinuria 
associated with a decrease of 8-iso-PGF2alpha formation in L-NAME-treated rats. J 
Hypertens 21: 601-609. 
46. Zhao, X., A. Dey, O. P. Romanko, D. W. Stepp, M. H. Wang, Y. Zhou, L. Jin, J. S. 
Pollock, R. C. Webb, and J. D. Imig. 2005. Decreased epoxygenase and increased 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
28 
 
epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am J Physiol 
Regul Integr Comp Physiol 288: R188-196. 
47. Dey, A., R. S. Williams, D. M. Pollock, D. W. Stepp, J. W. Newman, B. D. 
Hammock, and J. D. Imig. 2004. Altered kidney CYP2C and cyclooxygenase-2 levels are 
associated with obesity-related albuminuria. Obes Res 12: 1278-1289. 
48. Wang, M. H., A. Smith, Y. Zhou, H. H. Chang, S. Lin, X. Zhao, J. D. Imig, and A. 
M. Dorrance. 2003. Downregulation of renal CYP-derived eicosanoid synthesis in rats 
with diet-induced hypertension. Hypertension 42: 594-599. 
49. Zhou, Y., S. Lin, H.-H. Chang, J. Du, Z. Dong, A. M. Dorrance, M. W. Brands, and 
M.-H. Wang. 2005. Gender differences of renal CYP-derived eicosanoid synthesis in rats 
fed a high-fat diet*. American Journal of Hypertension 18: 530-537. 
50. Iyer, A., K. Kauter, M. A. Alam, S. H. Hwang, C. Morisseau, B. D. Hammock, and 
L. Brown. 2012. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-
induced metabolic syndrome in rats. Experimental diabetes research 2012: 758614. 
51. Wang, W., J. Yang, H. Yang, K. Z. Sanidad, B. D. Hammock, D. Kim, and G. 
Zhang. 2016. Effects of high-fat diet on plasma profiles of eicosanoid metabolites in mice. 
Prostaglandins & Other Lipid Mediators 127: 9-13. 
52. Chakrabarti, S. K., Y. Wen, A. D. Dobrian, B. K. Cole, Q. Ma, H. Pei, M. D. Williams, 
M. H. Bevard, G. E. Vandenhoff, S. R. Keller, J. Gu, and J. L. Nadler. 2011. Evidence for 
activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese 
Zucker rats. Am J Physiol Endocrinol Metab 300: E175-187. 
53. Martinez-Clemente, M., J. Claria, and E. Titos. 2011. The 5-
lipoxygenase/leukotriene pathway in obesity, insulin resistance, and fatty liver disease. 
Current opinion in clinical nutrition and metabolic care 14: 347-353. 
54. Gonzalez-Periz, A., R. Horrillo, N. Ferre, K. Gronert, B. Dong, E. Moran-Salvador, 
E. Titos, M. Martinez-Clemente, M. Lopez-Parra, V. Arroyo, and J. Claria. 2009. Obesity-
induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a 
role for resolvins and protectins. Faseb j 23: 1946-1957. 
55. Neuhofer, A., M. Zeyda, D. Mascher, B. K. Itariu, I. Murano, L. Leitner, E. E. 
Hochbrugger, P. Fraisl, S. Cinti, C. N. Serhan, and T. M. Stulnig. 2013. Impaired local 
production of proresolving lipid mediators in obesity and 17-HDHA as a potential 
treatment for obesity-associated inflammation. Diabetes 62: 1945-1956. 
56. Katakura, M., M. Hashimoto, T. Inoue, A. Al Mamun, Y. Tanabe, R. Iwamoto, M. 
Arita, S. Tsuchikura, and O. Shido. 2014. Omega-3 fatty acids protect renal functions by 
increasing docosahexaenoic acid-derived metabolite levels in SHR.Cg-Lepr(cp)/NDmcr 
rats, a metabolic syndrome model. Molecules 19: 3247-3263. 
57. Sharma, K., S. Ramachandrarao, G. Qiu, H. K. Usui, Y. Zhu, S. R. Dunn, R. 
Ouedraogo, K. Hough, P. McCue, L. Chan, B. Falkner, and B. J. Goldstein. 2008. 
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118: 1645-
1656. 
58. Tikoo, K., E. Sharma, V. R. Amara, H. Pamulapati, and V. S. Dhawale. 2016. 
Metformin Improves Metabolic Memory in High Fat Diet (HFD)-induced Renal 
Dysfunction. The Journal of biological chemistry 291: 21848-21856. 
59. Kim, D., J. E. Lee, Y. J. Jung, A. S. Lee, S. Lee, S. K. Park, S. H. Kim, B. H. Park, 
W. Kim, and K. P. Kang. 2013. Metformin decreases high-fat diet-induced renal injury by 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
29 
 
regulating the expression of adipokines and the renal AMP-activated protein 
kinase/acetyl-CoA carboxylase pathway in mice. Int J Mol Med 32: 1293-1302. 
60. Mount, P., M. Davies, S. W. Choy, N. Cook, and D. Power. 2015. Obesity-Related 
Chronic Kidney Disease-The Role of Lipid Metabolism. Metabolites 5: 720-732. 
61. Wang, W., X. H. Guo, H. H. Wu, N. H. Wang, and X. S. Xu. 2006. [Effect of 
fenofibrate and metformin on lipotoxicity in OLETF rat kidney]. Beijing da xue xue bao. Yi 
xue ban = Journal of Peking University. Health sciences 38: 170-175. 
62. Quehenberger, O., A. M. Armando, and E. A. Dennis. 2011. High sensitivity 
quantitative lipidomics analysis of fatty acids in biological samples by gas 
chromatography-mass spectrometry. Biochim Biophys Acta 1811: 648-656. 
63. Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. 
Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, C. M. Sullards, E. Wang, 
R. C. Murphy, R. M. Barkley, T. J. Leiker, C. R. Raetz, Z. Guan, G. M. Laird, D. A. Six, D. 
W. Russell, J. G. McDonald, S. Subramaniam, E. Fahy, and E. A. Dennis. 2010. 
Lipidomics reveals a remarkable diversity of lipids in human plasma. Journal of lipid 
research 51: 3299-3305. 
64. Dumlao, D. S., M. W. Buczynski, P. C. Norris, R. Harkewicz, and E. A. Dennis. 
2011. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-
acylethanolamines. Biochimica et biophysica acta 1811: 724-736. 
65. Xia, J., and D. S. Wishart. 2002. Using MetaboAnalyst 3.0 for Comprehensive 
Metabolomics Data Analysis. In Current Protocols in Bioinformatics. John Wiley & Sons, 
Inc. 
66. Afshinnia, F., L. Zeng, J. Byun, S. Wernisch, R. Deo, J. Chen, L. Hamm, E. R. 
Miller, E. P. Rhee, M. J. Fischer, K. Sharma, H. I. Feldman, G. Michailidis, and S. 
Pennathur. 2018. Elevated lipoxygenase and cytochrome P450 products predict 
progression of chronic kidney disease. Nephrol Dial Transplant. 
 
 
 
 
 
 
 
 
 
 
 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
AMPK ameliorates eicosanoids in HFD induced-CKD                                             Declèves et al. 
 
 
30 
 
Table 1: Eicosanoid metabolites altered with high-fat diet in the kidney 
Column1 Name Acronym MECH STD HFD 
p 
value 
q value 
Up with HFD        
Arachidonic acid metabolites       
 Arachidonic acid  AA PUFA 243.4±19.2 312.7±40.9 0.010 0.037 
 13,14-dihydro-15-keto-prostaglandin D2 dhk-PGD2 COX 0.04 ± 0.01 1.20 ± 0.02 0.008 0.035 
        
 5,6-epoxy-eicosotrienoic acid 5,6-EET P450 1.59 ± 0.74 8.64 ± 5.64 0.014 0.045 
 11,12-epoxy-eicosotrienoic acid 11,12-EET P450 0.02 ± 0.01 0.18 ± 0.13 0.015 0.045 
 5-oxo-eicosotetraenoic acid 5-oxoETE LOX 0.22 ± 0.11 1.56 ± 1.21 0.013 0.043 
 6(R),15(R)-lipoxin A4 
6(R),15(R)-
LXA4 LOX 0.02 ± 0.01 0.05 ± 0.02 0.006 0.032 
 6(S)-lipoxin A4 6SLXA4 LOX 0.02 ± 0.01 0.05 ± 0.02 0.015 0.045 
 9-hydroxy-eicosotetraenoic acid 9-HETE NE 0.02 ± 0.01 0.14 ± 0.09 0.013 0.043 
Docosahexaenoic acid metabolites       
 16,17-epoxy-docosapentenoic acid 16,17-EpDPE P450 0.42±0.07 0.65±0.08 0.001 0.010 
 16-hydroxy-docosahexaenoic acid  16-HDoHE P450 0.60±0.07 1.20±0.24 <0.001 0.003 
 19,20-epoxy-docosopentenoic acid 19,20-EpDPE P450 1.03±0.19 1.63±0.22 0.001 0.010 
 19,20-dihydroxy-docosapentenoic acid 19,20-DiHDPA P450 0.55±0.10 1.32±0.43 0.001 0.008 
 4-hydroxy-docosahexaenoic acid  4-HDoHE LOX 1.22±0.20 3.17±1.36 0.007 0.032 
 7-hydroxy-docosahexaenoic acid  7-HDoHE LOX 0.17±0.02 0.32±0.09 0.004 0.021 
 11-hydroxy-docosahexaenoic acid  11-HDoHE LOX 0.25±0.03 0.45±0.06 <0.001 0.001 
 17-hydroxy-docosahexaenoic acid  17-HDoHE LOX 1.04±0.13 1.84±0.31 <0.001 0.005 
 Protectin DX PDX LOX 0.02±0.01 0.07±0.02 0.009 0.037 
 15 (t)-protectin D1 15(t)-PD1 LOX 4.14±0.89 12.68±3.76 0.001 0.008 
 8-hydroxy-docosahexaenoic acid  8-HDoHE NE 0.67±0.08 1.16±0.24 0.001 0.009 
 10-hydroxy-docosahexaenoic acid  10-HDoHE NE 0.26±0.03 0.45±0.07 0.001 0.007 
 13-hydroxy-docosahexaenoic acid  13-HDoHE NE 0.51±0.10 0.78±0.11 0.003 0.017 
 20-hydroxy-docosahexaenoic acid  20-HDoHE NE 1.61±0.22 2.46±0.40 0.002 0.013 
Eicosapentaenoic acid metabolites       
 11-hydroxy-eicosapentaenoic acid 11-HEPE NE 0.28±0.10 2.0±1.50 0.010 0.037 
        
Down with HFD       
Arachidonic acid metabolites       
 Prostaglandin E2 PGE2 COX 2.88±1.02 1.43±0.21 0.011 0.040 
Dihomo-ϒ-linoleic acid metabolites       
 15-keto-Prostaglandin F1α 15-ketoPGF1α COX 0.43±0.09 0.23±0.08 0.007 0.032 
 15-hydroxy-eicosatrienoic acid 15-HETrE LOX 0.46±0.07 0.34±0.04 0.009 0.037 
Eicosapentaenoic acid metabolites       
 5-hydroxy-eicosapentaenoic acid 5-HEPE LOX 0.24±0.03 0.09±0.02 <0.001 0.001 
 12-hydroxy-eicosapentaenoic acid 12-HEPE LOX 4.23±0.31 1.17±0.26 <0.001 <0.001 
 15-hydroxy-eicosapentaenoic acid 15-HEPE LOX 0.15±0.02 0.05±0.01 <0.001 <0.001 
 18-hydroxy-eicosapentaenoic acid 18-HEPE NE 0.22±0.03 0.07±0.01 <0.001 <0.001 
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MECH- mechanism; STD – standard diet; HFD- high-fat diet; PUFA – polyunsaturated 
fatty acid; COX –cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; NE- non-
enzymatic degradation. All values are pmol/ mg renal tissue expressed as mean ± SD 
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Table 2: Eicosanoid metabolites altered with high-fat diet in the urine 
ColumnName Acronym MECH STD HFD p value q value
Up with HFD
Adrenic acid metabolites
Adrenic acid Adrenic Acid PUFA 0.018±0.009 0.27±0.27 0.001 0.011
Dihomo-prostaglandin F2α dihomo-PGF2α COX 0.009±0.003 0.62±0.18 <0.001 <0.001
Arachidonic acid metabolites
Arachidonic acid AA PUFA 1.768±0.619 14.7±8.9 <0.001 0.003
Prostaglandin A2 PGA2 COX 0.018±0.018 0.09±0.03 0.001 0.011
Prostaglandin B2 PGB2 COX 0.035±0.009 0.09±0.09 <0.001 0.005
13,14-dihydro-15- keto- prostaglandin E2 PGEM COX 0.354±0.035 1.23±0.17 <0.001 <0.001
Prostaglandin J2 PGJ2 COX 0.002±0.002 0.009±0.004 0.002 0.017
13,14-dihydro-15-keto-prostaglandin D2 dhk-PGD2 COX 0.008±0.003 0.026±0.004 <0.001 <0.001
6,15-diketo-13,14-dihydro-prostaglandin F1α 6,15 dk-,dh- PGF1α COX 0.27±0.09 2.12±0.79 <0.001 0.001
Prostaglandin F2α PGF2α COX 0.001±0.001 0.09±0.026 0.004 0.023
13,14-dihydro-15- keto-prostaglandin F2α PGFM COX 1.59±0.26 7.25±1.76 <0.001 <0.001
6-keto-prostaglandin E1 6kPGE1 COX 0.09±0.009 0.09±0.017 0.002 0.013
8,9-dihydroxy-eicosotrienoic acid 8,9-diHETrE P450 0.002±0.0009 0.006±0.0017 <0.001 0.001
11,12-epoxy-eicosatrienoic acid 11,12-EET P450 0.002±0.0009 0.005±0.002 0.002 0.013
Eoxin D4 EXD4 LOX 20.69±13.26 192.5±69.2 <0.001 0.001
Eoxin E4 EXE4 LOX 0.088±0.088 2.56±1.6 0.009 0.045
5-iso-prostaglandin F2α-VI 5-iso-PGF2α-VI NE 0.026±0.007 0.09±0.09 <0.001 0.001
8-iso-prostaglandin F2α 8-iso-PGF2α NE 0.08±0.009 0.17±0.09 0.008 0.042
Docosahexanoic acid metabolites
Protectin DX PDX LOX 11.22±13.96 27.5±8.7 0.008 0.042
19,20-dihydroxy-docosapentenoic acid 19,20-DiHDPA P450 0.009±0.006 0.026±0.017 0.009 0.046
Eicosopentaenoic acid metabolites
Prostaglandin E3 PGE3 COX 0.18±0.09 3.62±2.12 <0.001 0.000
Linoleic acid metabolites
9-oxo-octadecadienoic acid 9-oxoODE COX 2.39±0.97 54.7±2.1 0.001 0.011
Down with HFD
Eicosopentaenoic acid metabolites
Prostaglandin D3 PGD3 COX 0.71±0.26 0.17±0.17 0.003 0.021
Prostaglandin Fγα PGFγα COX 73739.8±35060.918813.4±15625.0 0.001 0.011
Thromboxane B3 TXB3 COX 0.044±0.009 0.026±0.009 0.008 0.042  
MECH- mechanism; STD – standard diet; HFD- high-fat diet; PUFA – polyunsaturated 
fatty acid; COX –cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; NE- non-
enzymatic degradation. All values are ng per mg creatinine expressed as mean ± SD. 
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Table 3: Eicosanoid metabolites altered with high-fat diet in the arterial circulation 
    
    
Column1 Name Acronym MECH STD HFD p value q value 
Up with HFD   
    
Arachidonic acid metabolites   
    
 Arachidonic acid AA PUFA 8771.3±1930.9 14906.2±2726.5 0.002 0.011 
 8,9-epoxy-eicosotrienoic acid 8,9-EET P450 0.10±0.14 3.77±3.41 0.001 0.005 
    
    
Down with HFD   
    
Alpha Linoleic acid metabolites   
    
 9-hydroxy-octatrienoic acid 9-HOTrE LOX 2.97±0.90 0.99±0.31 <0.001 0.003 
Docosahexaenoic acid metabolites   
    
 4-hydoxy-docosahexaenoic acid  4-HDoHE LOX 8.93±1.43 3.45±0.91 <0.001 0.001 
 11-hydoxy-docosahexaenoic acid  11-HDoHE LOX 3.03±1.13 1.35±0.80 0.014 0.042 
 16-hydoxy-docosahexaenoic acid  16-HDoHE P450 1.49±0.55 0.58±0.17 0.002 0.012 
 10-hydoxy-docosahexaenoic acid  10-HDoHE NE 2.56±0.92 1.05±0.52 0.009 0.031 
 13-hydoxy-docosahexaenoic acid  13-HDoHE NE 3.62±0.27 1.94±0.81 0.010 0.035 
 20-hydoxy-docosahexaenoic acid  20-HDoHE NE 1.49±0.62 0.11±0.10 0.002 0.012 
Eicosapentaenoic acid metabolites   
    
 Eicosapentaenoic acid EPA PUFA 12331.9±4377.1 4870.6±1329.8 0.003 0.016 
 5-hydroxy-eicosapentaenoic acid 5-HEPE LOX 2.53±0.28 0.38±0.13 <0.001 0.000 
 12-hydroxy-eicosapentaenoic acid 12-HEPE LOX 33.76±22.64 4.46±3.22 0.004 0.018 
 15-hydroxy-eicosapentaenoic acid 15-HEPE LOX 1.65±0.45 0.20±0.13 0.004 0.018 
 14(15)-epoxy-eicosatetraenoic acid 14,15-EpETE P450 0.56±0.18 0.18±0.05 <0.001 0.004 
 9-hydroxy-eicosapentaenoic acid 9-HEPE NE 3.56±1.84 0.11±0.13 <0.001 0.003 
 11-hydroxy-eicosapentaenoic acid 11-HEPE NE 1.45±0.18 0.18±0.07 <0.001 <0.001 
 18-hydroxy-eicosapentaenoic acid 18-HEPE NE 1.51±0.26 0.19±0.11 <0.001 <0.001 
Linoleic acid metabolites   
    
 9,10-dihydroxy-octadecaenoic acid 9,10-diHOME P450 16.71±6.03 7.38±4.10 0.013 0.042 
 12,13-epoxy-octadecenoic acid 12,13-EpOME P450 12.65±3.65 5.52±2.11 0.002 0.012 
 12,13-dihydroxy-octadecenoic acid 12,13-diHOME P450 38.64±13.16 10.86±6.82 0.001 0.008 
 13-hydroxy-octadecadienoic acid 13-HODE NE 61.13±20.15 23.91±8.93 0.005 0.018 
    
    
MECH- mechanism; STD – standard diet; HFD- high-fat diet; PUFA – polyunsaturated 
fatty acid; COX –cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; NE- non-
enzymatic degradation. All values are pmol/ml plasma expressed as mean ± SD. 
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Table 4: Eicosanoid metabolites altered with high-fat diet in the venous circulation 
Column1 Name Acronym MECH STD HFD p value q value 
Up with HFD    
  
  
Arachidonic acid metabolites   
  
  
 Arachidonic acid AA PUFA 7763.6±1110.5 13307.3±2881.1 0.001 0.009 
 8.9-epoxy-eicosotrienoic acid 8,9-EET P450 0.04±0.08 0.51±0.41 0.012 0.049 
 5,6-epoxy-eicosotrienoic acid 5,6-EET P450 8.26±4.66 20.49±6.51 0.006 0.031 
 11,12-epoxy-eicosotrienoic acid 11,12-EET P450 1.82±0.65 3.89±0.97 0.002 0.015 
 6-keto-prostaglandin F1α 6k-PGF1α COX 1.11±0.44 2.64±1.14 0.005 0.027 
    
  
  
Down with HFD   
  
  
Docosahexaenoic acid metabolites   
  
  
 4-hydroxy-docosahexaenoic acid  4-HDoHE LOX 9.87±2.09 3.26±0.61 <0.001 0.001 
 20-hydroxy-docosahexaenoic acid  20-HDoHE NE 0.89±0.33 0.13±0.22 0.004 0.027 
Alpha Linolenic acid metabolites   
  
  
 9-hydroxy-octatrienoic acid 9-HOTrE LOX 1.87±0.68 0.69±0.21 0.001 0.007 
Eicosapentaenoic acid metabolites   
  
  
 Eicosapentaenoic acid  EPA PUFA 10459.9±4175.6 4259.2±1425.1 0.008 0.035 
 9-hydroxy-eicosapentaenoic acid 9-HEPE NE 4.50±2.72 0.45±0.60 0.009 0.037 
 11-hydroxy-eicosapentaenoic acid 11-HEPE NE 1.06±0.22 0.21±0.10 <0.001 0.001 
 18-hydroxy-eicosapentaenoic acid 18-HEPE NE 1.11±0.22 0.14±0.06 <0.001 0.001 
 12-hydroxy-eicosapentaenoic acid 12-HEPE LOX 42.94±25.80 7.48±9.07 0.005 0.028 
 5-hydroxy-eicosapentaenoic acid 5-HEPE LOX 2.25±0.64 0.17±0.11 <0.001 0.001 
 15-hydroxy-eicosapentaenoic acid 15-HEPE LOX 1.36±0.74 0.07±0.10 0.001 0.009 
 
14(15)-epoxy-eicosatetraenoic 
acid 
14,15-
EpETE P450 
0.72±0.23 0.18±0.10 
0.001 0.007 
    
  
  
 
MECH- mechanism; STD – standard diet; HFD- high-fat diet; PUFA – polyunsaturated 
fatty acid; COX –cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; NE- non-
enzymatic degradation. All values are pmol/ml plasma expressed as mean ± SD. 
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Table 5 represents the trends in the kidney and urine of highly correlated metabolites 
using principal component (PC) analysis 
Variable  
PC 
variables  
PC 
Variance 
ANOVA             p-
value 
Post Hoc p-values   
   All STD vs. HFD 
HFD vs. 
HFDAICAR 
KIDNEY           
Arachidonic acid  
    
LOX 15 64.2 0.02 0.03 1 
COX 15 45.0 0.81 1 1 
P450 17 49.7 0.09 0.11 1 
13 PGR 2 60.6 0.06 0.11 1 
NE 3 42.2 0.20 0.34 1 
Eicosopentaenoic acid      
LOX 3 93.0 0.00002 0.00008 1 
NE 2 77.9 0.0000003 0.000001 1 
Docosahexaenoic acid     
LOX 4 77.2 0.007 0.006 0.28 
COX 2 96.0 0.001 0.001 0.03 
P450 2 97.5 0.003 0.003 0.08 
NE 4 95.8 0.008 0.007 0.12 
Dihomo-Ȗ-linolenic acid     
LOX 2 92.5 0.03 0.06 1 
Linoleic acid      
LOX 2 98.0 0.07 0.40 1 
NE 2 77.4 0.06 0.42 1 
Alpha-Linolenic acid      
LOX 3 82.4 0.26 0.89 0.33 
URINE           
Arachidonic acid  
    
LOX 28 46.3 0.06 0.42 0.95 
COX 27 33.6 0.0005 0.004 1 
P450 19 53.9 0.12 0.70 1 
13 PGR 3 47.7 0.03 0.04 1 
PGDH 5 45.6 0.00000002 0.00000001 0.00003 
NE 3 48.5 0.002 0.001 0.09 
Eicosopentaenoic acid      
LOX 3 96.8 0.14 0.214 0.33 
COX 5 50.8 0.00022 0.000161 0.03 
CYP 2 82.0 0.85 1 1 
NE 3 82.2 0.05 0.24 0.06 
Docosahexaenoic acid     
LOX 6 55.0 0.49 0.94 1 
COX 2 96.0 0.83 1 1 
NE 4 71.3 0.85 1 1 
Dihomo-Ȗ-linolenic acid     
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LOX 2 97.1 0.02 0.03 1 
Linoleic acid      
LOX 2 98.0 0.07 0.4 1 
NE 2 77.4 0.04 0.36 0.72 
Alpha-Linolenic acid      
LOX 3 82.4 0.26 0.88 0.33 
Adrenic acid     
COX 2 71.3 0.00002 0.00002 0.006 
 
PC principal components; PC variables -number of eicosanoids in the principal 
component; PC variance- amount of variance explained by the principal component; 
ANOVA p-value- p-value generated comparing all three groups; STD – standard diet; 
HFD- high-fat diet; HFD+AICAR -high-fat diet and AICAR therapy; COX –
cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; 13 PGR - delta13-15-
ketoprostaglandin reductase; PGDH-15-hydroxyprostaglandin dehydrogenase; NE- non-
enzymatic degradation; Red highlight elevated with HFD; Green highlight decreased with 
HFD; Yellow highlight elevated with AICAR; Blue highlight decreased with AICAR. 
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Table 6 represents the trends in the arterial and venous blood of highly correlated 
metabolites using principal component (PC) analysis 
Variable  
PC 
variables  
PC 
Variance 
ANOVA          p-
value 
Post Hoc p-values   
   All STD vs. HFD 
HFD vs. 
HFDAICAR 
ARTERY           
Arachidonic acid  
    
LOX 9 40.9 0.73 1 1 
13 PGR 2 70.3 0.42 0.60 1 
COX 6 59.9 0.90 1 1 
P450 13 49.3 0.13 0.43 0.16 
Eicosopentaenoic 
acid  
    
LOX 3 78.9 0.000003 0.00004 0.72 
Docosahexaenoic 
acid 
    
LOX 2 79.9 0.001 0.003 1 
P450 2 78.1 0.01 0.03 1 
NE 4 77.1 0.01 0.01 1 
Linoleic acid      
NE 2 92.8 0.32 0.43 0.97 
Alpha-Linolenic acid      
LOX 3 75.7 0.04 0.03 0.37 
VEIN           
Arachidonic acid  
    
LOX 8 59.4 0.87 1 1 
13 PGR 2 50.5 0.06 0.06 0.47 
COX 5 67.2 0.84 1 1 
P450 15 47.9 0.12 1 0.19 
Eicosopentaenoic 
acid  
    
LOX 3 78.0 0.00002 0.00003 0.60 
NE 2 82.4 0.00004 0.0003 1 
Docosahexaenoic 
acid 
    
LOX 3 58.0 0.0004 0.002 1 
NE 3 73.9 0.08 0.09 0.76 
Linoleic acid      
NE 2 90.4 0.11 0.79 0.11 
Alpha-Linolenic acid      
LOX 3 73.7 0.02 0.03 0.09 
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PC principal components; PC variables -number of eicosanoids in the principal 
component; PC variance- amount of variance explained by the principal component; 
ANOVA p-value- p-value generated comparing all three groups; STD – standard diet; 
HFD- high-fat diet; HFD+AICAR -high-fat diet and AICAR therapy; COX –
cyclooxygenase; LOX –lipoxygenase; P450-cytochrome P450; 13 PGR - delta13-15-
ketoprostaglandin reductase; PGDH-15-hydroxyprostaglandin dehydrogenase; NE- non-
enzymatic degradation; Green highlight demonstrates decreased with HFD. 
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Figure 1 
 
Figure 1.  High-fat diet increases cytosolic phospholipase A2 and secretory-
phospholipase A2 levels in the mouse kidney that is improved with AICAR 
treatment. Western blot analysis of the effect of standard (STD), high-fat diet (HFD) 
and HFD with AICAR (HFD+AICAR) treatment on cytosolic phospho-phospholipase 
A2 (pPLA2) and secretory- phospholipase A2 (sPLA2) in mice kidney. Relative 
densitometry of the immunoblots were normalized with beta-actin. Values are means 
± SD. N=5 in each group. *p<0.05. 
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Figure 2 
 
Figure 2. High fat diet increases free and total polyunsaturated fatty acid levels 
in the mouse kidneys that is rescued by AMPK activation 
Total and free levels of ω3 fatty acids eicosapentaenoic acid (EPA, panels A and B) 
and docosahexaenoic acid (DHA, panels C and D) and ω6 fatty acids – dihommo 
gamma-linolenic acid (DGLA, panels E and F) and arachidonic acid (AA, panels G and 
H) in the mice fed standard (STD), high fat diet (HFD), and HFD with AICAR.  Values 
are means ± SD. N=6 in each group. *p<0.05 
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Figure 3 
 
Figure 3. Profile of eicosanoid species modulated by high-fat diet and AMPK 
activation in mouse kidneys. 
Eicosanoids profiles show changes in the kidneys of mice fed standard (STD), high-fat 
diet (HFD), and HFD with AICAR. Values are means ± SD. N=6 in each group. 
Statistical analyses were performed by one-way ANOVA followed by Fisher post hoc 
tests. All p values corrected for Bonferroni FDR correction of *q ≤ 0.05. Arachidonic 
acid metabolite of cytochrome P450 12-hydroxyl-hexadecatrienoic acid (12HHT; Panel 
A); Docosahexaenoic acid metabolites of cytochrome P450: 19,20-dihydroxy-
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docosapenatenoic acid (19,20-DHDPA, Panel B); 16-hydroxy-docosahexaenoic acid 
(16-HDoHE; Panel C); Lipoxygenase metabolites: 15 (t) Protectin D1 (15(t)-PD1, Panel 
D), 7-hydroxy-docosahexaenoic acid (7-HDoHE; Panel E), and 11-hydroxy-
docosahexaenoic acid (11-HDoHE; Panel F); and non-enzymatic process: 8-hydroxy-
docosahexaenoic acid (18-HDoHE; Panel G) and 13-hydroxy-docosahexaenoic acid 
(13-HDoHE; Panel H).  
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Figure 4 
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Figure 4. Profile of urinary eicosanoid species in mice on high-fat diet and 
AICAR. 
Eicosanoid species in urine were normalized for concentration with creatinine levels in 
standard diet (STD), high-fat diet (HFD) and HFD with AICAR therapy. Values are 
means ± SD of original data or normalized data (log transformed, auto scaled) 
represented as box plots with whiskers (median, Interquartile interval). N=6 in each 
group. Statistical analyses were performed by one-way ANOVA by Fisher post hoc 
tests. All p values corrected for Bonferroni FDR correction of *q ≤ 0.05. Adrenic acid 
metabolites- dihomo-prostaglandin PGF2α (dihomo-PGF2α, Panel A), dihomo-15-
deoxyprostaglandin D2 (dihomo-15d-PGD2, Panel B). Urine arachidonic acid (AA, 
Panel C) and its cyclooxygenase metabolites- 13,14-dihydro-15-keto-prostaglandin E2 
(PGEM, Panel D); 13,14-dihydro-5-keto-prostaglandin F2α (PGFM, Panel E); 
Prostaglandin F2α (PGF2α, Panel F); 13,14-dihydro-15-keto-prostaglandin D2 (dhk-
PGD2, Panel G); non-enzymatic product 5-iso-prostaglandin F2α-VI (5-iso-PGF2α-VI, 
Panel H). Cyclooxygenase metabolites of eicosapentaenoic acid- Prostaglandin E3 
(PGE3, Panel I) and Thromboxane B3 (TXB3, Panel J). 
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Figure 5 
 
 
 
Figure 5. Profile of eicosanoid species in the circulation regulated by high-fat 
disease and AICAR. 
Profile of eicosanoid species in arterial and venous circulation in mice fed a standard 
diet (STD), high-fat diet (HFD) or HFD with AICAR therapy. Values are means ± SD. 
N=6 in each group. Statistical analyses were performed by one-way ANOVA followed 
by Fisher post hoc tests. All p values corrected for Bonferroni FDR correction of *q ≤ 
0.05. Linoleic acid metabolites of cytochrome P450 in the artery- 9,10-dihydroxy-
octadecaenoic acid (9, 10-diHOME, Panel A), 12,13-epoxy-octadecenoic acid (12,13-
EpHOME, Panel B), and 12,13-dihydroxy-octadecenoic acid (12,13-diHOME, Panel 
C). Venous Lipoxygenase metabolite of alpha-linolenic acid- 9-hydroxy-octatrienoic 
acid (9-HOTrE, Panel D) and eicosapentaenoic acid- 5-hydroxy-eicosapentaenoic acid 
(5-HEPE, Panel E). 
 
 at Univ of California - San Diego Serials/Biom
ed Lib 0699, on M
arch 18, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
Figure 6. Schematic diagram of the eicosanoid metabolites regulated by AMPK 
activation to reverse the effects of high-fat diet in the kidney, urine, arterial and 
venous circulation.  
 
Adrenic acid metabolites-dihomo-prostaglandin PGF2α (dihomo-PGF2α) and dihomo-
15-deoxy prostaglandin D2 (dihomo-15d-PGD2); Arachidonic acid (AA) metabolites- 
13,14-dihydro-15-keto-prostaglandin E2 (PGEM) and 13,14-dihydro-5-keto-
prostaglandin F2α (PGFM), and Prostaglandin F2α (PGF2α); Eicosapentaenoic acid 
(EPA) metabolites -Prostaglandin E3 (PGE3), Thromboxane B3 (TXB3) and 5-hydroxy-
eicosapentaenoic acid (5-HEPE); Alpha – Linolenic acid (ALA) metabolite- 9-hydroxy-
octatrienoic acid (9-HOTrE); Docosahexaenoic acid (DHA) metabolites-19,20-
dihydroxy-docosapentenoic acid (19,20-DiHDPA),16-hydroxy-docosahexanoic acid 
(16-HDoHE), 15 (t)- Protectin D1(15(t)-PD1), 7-hydroxy-docosahexaenoic acid (7-
HDoHE), 11-hydroxy-docosahexanoic acid (11-HDoHE), 8-hydroxy-docosahexanoic 
acid (8-HDoHE); 13-hydroxy docosahexaenoic acid (13-HDoHE); and finally Linoleic 
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acid metabolite-9,10-dihydroxy-octadecaenoic acid (9,10-diHOME); 12,13, Epoxy-
octadecaenoic acid (12,13-EpOME) and, 12,13,dihydroxyoctadecenoic acid (12,13-
diHOME). P450- cytochrome P450; LOX – lipoxygenases; COX – cyclooxygenase; NE 
–non-enzymatic. Red font indicates that high-fat diet increases these metabolites and 
AICAR reverses this, while blue font indicates the metabolite is decreased with high-
fat diet and AICAR reverses this trend. 
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Supplemental Table S1. Total fatty acid (FA) (esterified and unesterified FA) and free FA (unesterified, FFA) profiles generated from the kidney of mice fed a low 
fat, standard chow (STD), HFD or HFD with the AMPK activator AICAR (HFD+AICAR)  
 Name Acronym STD HFD HFD+AICAR 
p.value     
STD vs HFD 
FDR         
STD vs HFD 
p.value 
ANOVA 
FDR 
ANOVA 
Total Fatty Acids (pmol/mg) 
1 Lauric acid 12:0 113.8±43.7 107.32±68.64 136.06±107.07 0.623 0.688 0.880 0.939 
2 Myristic acid 14:0 509.26±325.48 377.07±201.08 279.34±100.17 0.703 0.750 0.620 0.709 
3 Pentadecanoic acid 15:0 116.02±22.47 91.2±29.13 74.96±21.75 0.148 0.237 0.082 0.197 
4 Palmitic  acid 16:0 11296.42±1178.66 11037.4±1518.56 11327.56±38.66 0.749 0.773 0.952 0.952 
5 Palmitoleic  acid 16:1 673.58±454.33 794.32±1092.33 352.16±264.06 0.592 0.676 0.415 0.531 
6 Margaric acid 17:0 215.78±17.30 191.92±29.28 219.98±71.14 0.156 0.237 0.620 0.709 
7 Heptadecenoic  acid 17:1 38.2±19.69 73.92±80.87 38.16±23.63 0.532 0.631 0.665 0.734 
8 Stearic  acid 18:0 7072.54±480.45 7533.62±1106.65 7712.4±2610.78 0.514 0.631 0.916 0.945 
9 Oleic  acid 18:1 2103.92±295.41 2720.78±395.47 3291.42±998.03 0.024 0.065 0.031 0.111 
10 Linoleic   acid 18:2 6441.18±992.92 5556.98±437.79 7099.84±2237.18 0.115 0.197 0.309 0.430 
11 α-linolenic  acid 18:3 N3 55.2±20.59 50.12±12.24 80.16±34.36 0.793 0.793 0.216 0.340 
12 γ-linolenic  acid 18:3 N6 338.16±87.45 231.02±79.04 272.04±110.77 0.062 0.142 0.219 0.340 
13 Stearidonic acid 18:4 3.78±0.89 3.06±0.56 8.12±5.76 0.180 0.250 0.157 0.279 
14 Arachidic acid 20:0 12125.58±615.62 41.7±5.51 47.78±26.86 0.001 0.003 0.144 0.272 
15 Eicosaenoic acid 20:1 83.32±42.52 73.92±52.95 53.58±31.50 0.531 0.631 0.494 0.608 
16 Eicosadienoic acid 20:2 276.74±48.97 381.55±96.99 336.8±93.59 0.083 0.176 0.223 0.340 
17 Eicosatrienoic  acid 20:3 N3 9.04±4.79 3.83±1.47 2.9±1.24 0.045 0.110 0.025 0.100 
18 Bishomo-γ-linolenic acid 20:3 N6 645.14±75.59 474.05±65.27 494.36±139.85 0.006 0.020 0.044 0.141 
19 5,8,11-Eicosatrienoic acid 20:3 N9 30.38±6.24 86.63±16.89 72.86±17.91 <0.001 <0.001 <0.001 <0.001 
20 Arachidonic acid 20:4 12125.58±615.67 15756.66±1501.57 15817.94±44 0.001 0.003 0.055 0.160 
21 Eicosapentaenoic acid 20:5 224.94±29.74 104.02±42.67 73.26±22.30 0.001 0.005 <0.001 0.001 
22 Behenic acid 22:0 30.44±24.46 0 4.12±5.15 <0.001 <0.001 <0.001 0.001 
23 cis-Erucic acid acid 22:1 0.56±0.69 0 0 0.104 0.196 0.086 0.197 
24 Docosadienoic acid 22:2 0.14±0.15 0.02±0.04 0.02±0.04 0.097 0.194 0.101 0.202 
25 Adrenic acid 22:4 12.08±2.53 30.33±8.23 26.82±7.41 <0.001 0.003 <0.001 0.002 
26 
Docosapentaenoic ω-3 
acid 22:5 N3 
38.38±5.66 111.42±32.16 99.64±27.51 <0.001 0.001 <0.001 0.001 
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27 
Docosapentaenoic ω-6 
acid 22:5 N6 
38.32±5.69 74.9±20.05 50.36±13.51 0.003 0.009 0.005 0.021 
28 Docosahexaenoic acid 22:6 924.14±130.52 2271.36±538.80 1700.7±482.66 <0.001 0.001 <0.001 0.001 
29 Tricosanoic acid 23:0 1.6±0.62 1.08±1.42 1.04±1.04 0.117 0.197 0.279 0.405 
30 Lignoceric acid 24:0 13.34±11.01 2.63±4.04 11.38±9.53 0.015 0.044 0.084 0.197 
31 cis-Selacholeic  acid 24:1 1.58±0.39 1.28±0.76 0.78±0.41 0.283 0.378 0.094 0.200 
32 Cerotic  acid 26:1 6.18±9.61 0.52±1.15 3.74±7.48 0.171 0.249 0.382 0.510 
 Name Acronym STD HFD HFD+AICAR 
p.value     
STD vs HFD 
FDR         
STD vs HFD 
p.value 
ANOVA 
FDR 
ANOVA 
Free Fatty Acids (pmol/mg) 
1 Lauric acid 12:0 15.68±15.50 7.18±8.33 57.07±55.86 0.623 0.688 0.278 0.569 
2 Myristic acid 14:0 38.4±24.04 24.62±15.85 43.52±39.63 0.703 0.750 0.755 0.872 
3 Pentadecanoic acid 15:0 7.92±6.12 4.35±2.52 12.23±4.75 0.148 0.237 0.071 0.269 
4 Palmitic  acid 16:0 959.04±315.02 795.55±133.79 884.17±248.61 0.749 0.773 0.752 0.872 
5 Palmitoleic  acid 16:1 29.1±7.16 22.4±9.92 30.08±19.80 0.592 0.676 0.624 0.872 
6 Margaric acid 17:0 11.12±6.11 12.31±7.29 14.55±6.71 0.156 0.237 0.696 0.872 
7 Heptadecenoic  acid 17:1 2.66±0.70 2.96±1.39 4.72±1.94 0.532 0.631 0.230 0.522 
8 Stearic  acid 18:0 602±326.84 348.12±168.69 671.9±219.04 0.514 0.631 0.103 0.323 
9 Oleic  acid 18:1 360.26±83.69 397.6±99.28 399±120.81 0.024 0.065 0.821 0.872 
10 Linoleic   acid 18:2 613±117 486.4±72.3 552.6±148 0.115 0.197 0.351 0.628 
11 α-linolenic  acid 18:3 N3 4.6±1.2 5.4±1.1 6.3±3.3 0.062 0.142 0.810 0.872 
12 γ-linolenic  acid 18:3 N6 35.7±10.6 25.5±5.3 37±15 0.793 0.793 0.325 0.613 
13 Stearidonic acid 18:4 0.9±0.4 0.9±0.3 1.3±0.8 0.180 0.250 0.885 0.912 
14 Arachidic acid 20:0 6.6±3.4 3±1.5 6.9±3.1 0.001 0.003 0.067 0.269 
15 Eicosaenoic acid 20:1 4.1±1.4 3.6±1 5.3±2 0.531 0.631 0.483 0.775 
16 Eicosadienoic acid 20:2 20.6±3 27.1±6.5 25±5.7 0.083 0.176 0.201 0.522 
17 Eicosatrienoic  acid 20:3 N3 0.4±0.3 0.2±0.2 0.1±0.2 0.045 0.110 0.147 0.418 
18 Bishomo-γ-linolenic acid 20:3 N6 34.2±5.5 24.6±5.4 22.2±3 0.006 0.020 0.005 0.035 
19 5,8,11-Eicosatrienoic acid 20:3 N9 2.4±0.9 4.4±1.3 3.9±1.4 <0.001 <0.001 0.068 0.269 
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20 Arachidonic acid 20:4 391.6±32 481.7±45.4 384.1±14.2 0.001 0.003 0.001 0.009 
21 Eicosapentaenoic acid 20:5 47.5±3.3 19.3±2.9 14.9±2.6 0.001 0.005 <0.001 <0.001 
22 Behenic acid 22:0 3.5±1.6 2.8±1.1 4.8±2.2 <0.001 <0.001 0.451 0.767 
23 cis-Erucic acid acid 22:1 6.2±3.3 3±1.7 2.4±1.2 0.104 0.196 0.216 0.522 
24 Docosadienoic acid 22:2 1.9±0.5 2±0.3 1.9±0.7 0.097 0.194 0.760 0.872 
25 Docosatrienoic acid 22:3 0.2±0.3 0.1±0.1 0.2±0.3 0.820 0.924 0.958 0.958 
26 Adrenic acid 22:4 16.3±5.3 22.4±3.3 19.6±4.17 <0.001 0.003 0.105 0.323 
27 Docosapentaenoic ω-3/ 22:5 N3 18±2.5 29.3±4.2 28.2±5.3 <0.001 0.001 0.001 0.009 
28 
Docosapentaenoic ω-6 
acid 22:5 N6 
41.4±7.4 36.4±8.5 27.2±6.1 0.003 0.009 0.025 0.141 
29 Docosahexaenoic acid 22:6 412.5±60.5 570.8±89.5 396.2±66.3 <0.001 0.001 0.005 0.035 
30 Tricosanoic acid 23:0 0.2±0.2 0.1±0.1 0.4±0.3 0.117 0.197 0.284 0.569 
31 Lignoceric acid 24:0 2.5±1.1 1.9±1.2 3±1.8 0.015 0.044 0.657 0.872 
32 cis-Selacholeic  acid 24:1 0.3±0.1 0.4±0.1 0.5±0.2 0.283 0.378 0.816 0.872 
33 Cerotic  acid 26:1 63±87 99±146 398.4±610.3 0.171 0.249 0.501 0.775 
  
MECH- mechanism; STD – standard diet; HFD- high fat diet; HFD +AICAR – HFD with AICAR therapy; PUFA – polyunsaturated fatty acid; COX –cyclooxygenase; LOX 
–lipoxygenase; CYT-cytochrome P450 oxidase; NE- non-enzymatic degradation; P value for two way ANOVA; FDR- False discovery rate; for the comparison of STD, HFD, 
and HFD with AICAR. 
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Supplemental Figure S1. Delta-6-desaturase, delta-5-desaturase, and elongase 5 levels are unchanged in the kidney with high fat diet and AMPK activation  
 
 
 
 
 
 
 
 
 
 
 
 
 
Western blot analysis of the effect of high fat diet (HFD) and AMPK activator -AICAR on delta-5-desaturase (D5D; FADS1), delta-6-desaturase (D6D; FADS2), and elongase 
5 (ELOLV5) in standard (STD), high fat diet (HFD) and HFD+AICAR-treated mice. Relative densitometry of the immunoblots did not show a difference between groups. All 
figures were normalized with beta-actin. Values are means ± SD. N=5 in each group.  
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Supplementary Table S2. Significant eicosanoid metabolites altered with high fat diet and AMP activation in the kidney, urine, arterial and venous circulation 
  NAME ACRONYM PARENT MECH STD HFD HFD+AICAR p.value FDR Fisher's LSD 
KIDNEY(pmol/mg)                   
1 Arachidonic acid AA AA PUFA 243.4±19.2 312.7±40.9 237.4±18.7 0.002 0.013 2 - 1; 2 - 3 
2 9-hydroxy-eicosatetraenoic acid 9-HETE AA NE 0.02±0.01 0.14±0.09 0.08±0.03 0.006 0.025 2 - 1; 3 - 1 
3 12-oxo-eicosatrienoic acid 12-oxoETE AA LOX 2.73±0.34 12.28±9.19 8.72±2.78 0.014 0.039 2 - 1; 3 - 1 
4 Hepoxilin B3 HXB3 AA LOX 0.26±0.05 0.94±0.60 0.65±0.18 0.021 0.050 2 - 1; 3 - 1 
5 5-oxo-eicosatetraenoic acid 5-oxoETE AA LOX 0.21±0.11 2.55±1.70 1.21±0.49 0.004 0.024 2 - 1; 3 - 1 
6 15-oxo-eicosatetraenoic acid 15-oxoETE AA LOX 0.51±0.21 2.55±1.70 1.71±0.58 0.014 0.039 2 - 1; 3 - 1 
7 6(t),12, epi-Leukotriene B4 6t,12-epiLTB4 AA LOX 0.01±0.00 0.02±0.01 0.02±0.00 0.014 0.039 2 - 1; 3 - 1 
8 
6(R), 15(R) Lipoxin A4 
6(R),15(R)-
LXA4 
AA LOX 0.02±0.01 0.05±0.02 0.05±0.01 0.004 0.024 
2 - 1; 3 - 1 
9 6(S)-lipoxin A4 6(S)-LXA4 AA LOX 0.02±0.01 0.05±0.02 0.05±0.02 0.009 0.028 2 - 1; 3 - 1 
10 11,12-epoxy-eicosatrienoic acid 11,12-EET AA P450 0.02±0.01 0.18±0.13 0.13±0.05 0.005 0.025 2 - 1; 3 - 1 
11 5,6-epoxy-eicosatrienoic acid 5, 6-EET AA P450 1.59±0.74 8.64±5.64 5.72±1.95 0.007 0.025 2 - 1; 3 - 1 
12 8,9-epoxy-eicosatrienoic acid 8, 9-EET AA P450 0.04±0.01 0.16±0.10 0.12±0.04 0.011 0.032 2 - 1; 3 - 1 
13 Prostaglandin E2 PGE2 AA COX 2.88±1.02 1.43±0.21 1.32±0.49 0.006 0.025 1 - 2; 1 - 3 
14 12-hydroxy-heptadecatrenoic acid  12-HHT AA COX 7.63±0.41 9.13±1.36 5.94±0.93 <0.001 0.005 1 - 3; 2 - 3 
15 
13,14-dihydro-15-keto-
prostaglandin D2 
dhk-PGD2 AA 13PGR 0.04±0.01 0.08±0.02 0.09±0.02 0.001 0.008 
2 - 1; 3 - 1 
16 15-dehydro- Prostaglandin F1α 15k-PGF1α DGLA PGDH 0.43±0.10 0.23±0.07 0.14±0.03 <0.001 0.002 1 - 2; 1 - 3; 2 - 3 
17 15-hydroxy-eicosotrienoic acid 15-HETrE DGLA LOX 0.46±0.07 0.34±0.04 0.33±0.06 0.009 0.028 1 - 2; 1 - 3 
18 8-hydroxy-docosahexanoic acid 8-HDoHE DHA NE 0.67±0.08 0.36±0.24 0.81±0.22 0.006 0.025 2 - 1; 2 - 3 
19 13-hydroxy-docosahexanoic acid 13-HDoHE DHA NE 0.51±0.08 2.92±0.11 0.61±0.13 0.011 0.032 2 - 1; 2 - 3 
20 20-hydroxy-docosahexanoic acid 20-HDoHE DHA NE 1.61±0.22 2.46±0.40 2.05±0.50 0.017 0.042 2-1; 
21 10-hydroxy-docosahexanoic acid 10-HDoHE DHA NE 0.26±0.03 0.45±0.07 0.35±0.10 0.007 0.027 2-1; 
22 15(t)- Protectin D1 15(t)-PD1 DHA LOX 4.14±0.89 12.69±3.76 6.22±2.11 0.001 0.007 2 - 1; 2 - 3 
23 7-hydroxy- docosahexaenoic acid 7-HDoHE DHA LOX 0.17±0.02 0.31±0.09 0.21±0.05 0.008 0.028 2 - 1; 2 - 3 
24 4-hydroxy- docosahexanoic acid 4-HDoHE DHA LOX 1.22±0.19 3.17±1.36 2.57±0.63 0.005 0.025 2 - 1; 3 - 1 
25 
10(S), 17(S)-dihydroxy- 
docosahexanoic acid 
10(S),17(S)-
DiHDoHE 
DHA LOX 0.02±0.01 0.07±0.02 0.04±0.01 0.008 0.028 
2-1; 
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26 
19,(20)-dihydroxy-
docosapentenoic acid 
19,20-
DiHDPA 
DHA P450  0.55±0.10 1.32±0.43 0.73±0.12 <0.001 0.005 
2 - 1; 2 - 3 
27 11-hydroxy-docosahexanoic acid 11-HDoHE DHA P450 0.24±0.03 0.45±0.06 0.30±0.08 <0.001 0.006 2 - 1; 2 - 3 
28 16-hydroxy-docosahexanoic acid 16-HDoHE DHA P450 0.60±0.07 1.20±0.24 0.84±0.20 0.001 0.007 2 - 1; 3 - 1; 2 - 3 
29 
16,(17)-epoxy-docasapentaienoic 
acid 
16,17-EpDPE DHA P450 0.42±0.07 0.65±0.08 0.51±0.13 0.015 0.039 
2-1; 
30 
19,(20)-epoxy-docosapentaenoic 
acid 
19,20-EpDPE DHA P450 1.03±0.19 1.63±0.22 1.32±0.35 0.016 0.040 
2-1; 
31 17-hydroxy-docosahexanoic acid 17-HDoHE DHA COX 1.04±0.13 1.84±0.31 1.43±0.38 0.004 0.024 2-1; 
32 
18-hydroxy-eicosapentaenoic acid 
18-HEPE EPA NE 0.22±0.03 0.07±0.01 0.06±0.02 <0.001 
<0.00
1 1 - 2; 1 - 3 
33 
12-hydroxy-eicosapentaenoic acid 
12-HEPE EPA LOX 4.23±0.31 1.17±0.26 1.25±0.36 <0.001 
<0.00
1 1 - 2; 1 - 3 
34 15-hydroxy-eicosapentaenoic acid 15-HEPE EPA LOX 0.15±0.02 0.05±0.01 0.06±0.03 0.001 0.009 1 - 2; 1 - 3 
35 5-hydroxy-eicosapentaenoic acid 5-HEPE EPA LOX 0.24±0.03 0.09±0.02 0.08±0.03 <0.001 0.002 1 - 2; 1 - 3 
36 11-hydroxy-eicosapentaenoic acid 11-HEPE EPA COX 0.28±0.10 1.99±1.51 1.23±0.44 0.004 0.024 2 - 1; 3 - 1 
37 9-oxo-octadecadienoic acid 9-oxoODE LA NE 4.49±1.02 7.80±2.77 9.47±2.95 0.006 0.025 2 - 1; 3 - 1 
   
          
URINE (ng/mg Creatinine)                   
  NAME ACRONYM PARENT MECH STD HFD HFD+AICAR p.value FDR Fisher's LSD 
1 Arachidonic acid AA AA PUFA 1.77±0.62 14.69±8.94 5.75±1.68 <0.001 0.001 2 - 1; 3 - 1; 2 - 3 
2 
5-iso-Prostaglandin F2α-VI 
5-isoPGF2α-VI AA NE 0.03±0.01 0.12±0.04 0.075±0.012 <0.001 
<0.00
1 2 - 1; 3 - 1; 2 - 3 
3 
20-carboxylic-Leucotrine B4 
20cooh-LTB4 AA LOX 14.07±8.23 
13.45±26.1
9 
0.02±0.01 0.009 0.034 
1 - 2; 1 - 3 
4 
Eoxin D4 
EXD4 AA LOX 20.71±13.28 
192.67±69.
30 
401.97±300.5
5 
<0.001 
<0.00
1 2 - 1; 3 - 1 
5 Eoxin E4 EXE4 AA LOX 0.09±0.09 2.57±1.59 1.95±1.68 0.003 0.013 2 - 1; 3 - 1 
6 
12-hydroxy-eicosatetraenoic acid 
12-HETE AA LOX 
0.0062±0.00
62 
0.02±0.01 0.09±0.004 0.003 0.017 
2 - 1; 3 - 1 
7 
Leuckotriene E4 
LTE4 AA LOX 
0.0009±0.00
09 
0.002±0.00
09 
0.004±0.002 0.004 0.018 
2 - 1; 3 - 1 
8 5-hydroxy-eicosatetraenoic acid 5-HETE AA LOX 0.03±0.04 0.06±0.04 0.06±0.03 0.009 0.034 2 - 1; 3 - 1 
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9 
11(t)-Leukotriene D4 
11(t)-LTD4 AA LOX 
0.0009±0.00
2 
0.0004±0.0
004 
0.004±0.004 0.002 0.012 
3 - 1; 3 - 2 
10 
Leukotriene D4 
LTD4 AA LOX 8.76±3.36 
26.28±16.4
6 
97.88±111.33 0.007 0.028 
3 - 1; 3 - 2 
11 
11,12-epoxy-eicosatrienoic acid 
11,12-EET AA P450 
0.002±0.000
9 
0.0053±0.0
026 
0.0062±0.002
7 
0.001 0.007 
2 - 1; 3 - 1 
12 17-hydroxy-eicosatetraenoic acid 17-HETE AA P450 0.03±0.03 0.11±0.05 0.50±0.30 0.003 0.013 2 - 1; 3 - 1 
13 
8,9-dihydroxy-eicosotrienoic acid 
8, 9-diHETrE AA P450 
0.002±0.000
9 
0.0062±0.0
017 
0.009±0.0089 0.004 0.019 
2 - 1; 3 - 1 
14 
13,14-dihydro-15-keto-
Prostaglandin F2α 
PGFM AA COX 1.59±0.26 7.26±1.77 3.01±0.44 <0.001 
<0.00
1 2 - 1; 3 - 1; 2 - 3 
15 
13,14-dihydro-15-keto-
Prostaglandin A2 
PGEM AA COX 0.35±0.035 1.24±0.18 0.53±0.18 <0.001 
<0.00
1 2 - 1; 3 - 1; 2 - 3 
16 
Prostaglandin F2α 
PGF2α AA COX 0.009±0.008 
0.056±0.02
2 
0.02±0.01 0.004 0.019 
2 - 1; 2 - 3 
17 
6,15-diketo-13,14-dihydro 
Prostaglandin F1α 
6,15-dk,dh-
PGF1α 
AA COX 0.26±0.09 2.12±0.8 2.74±1.33 <0.001 
<0.00
1 2 - 1; 3 - 1 
18 Prostaglandin B2 PGB2 AA COX 0.04±0.009 0.09±0.09 0.2±0.2 <0.001 0.001 2 - 1; 3 - 1 
19 Prostaglandin A2 PGA2 AA COX 0.02±0.02 0.09±0.04 0.18±0.09 <0.001 0.001 2 - 1; 3 - 1 
20 Prostaglandin J2 PGJ2 AA COX 0.002±0.002 0.01±0.004 0.01±0.005 0.001 0.008 2 - 1; 3 - 1 
21 
Thromboxane B2 
TXB2 AA COX 0.035±0.009 0.02±0.002 0.08±0.03 <0.001 
<0.00
1 3 - 1; 3 - 2 
22 
2,3 dinoor-11 β-Prostaglandin F2α 
2,3-dinoor-
11β-PGF2α 
AA COX 682.3±129.4 
1197.3±67
9.2 
2510.8±1119.
3 
0.002 0.012 
3 - 1; 3 - 2 
23 
13,14-dihydro-15-keto-
prostaglandin D2 
dhkPGD2 AA 13PGR 0.01±0.002 0.03±0.004 0.01±0.005 <0.001 0.002 
2 - 1; 2 - 3 
24 Adrenic acid Adrenic Adrenic PUFA 0.01±0.01 0.25±0.22 0.06±0.02 <0.001 0.002 2 - 1; 3 - 1 
25 
Dihomo-15-deoxyprostaglandin 
D2 
dihomo15dP
GD2 
Adrenic COX 323.2±571.7 77.0±77.6 202.4±233.8 0.015 0.047 
1 - 2; 3 - 2 
26 
Dihomo-prostaglandin F2α 
dihomoPGF2
α 
Adrenic COX 0.01±0.003 0.62±0.18 0.44±0.62 <0.001 
<0.00
1 2 - 1; 3 - 1; 2 - 3 
27 15-dehydro-Prostaglandin F1α 15kPGF1α DGLA PGDH 0.02±0.005 0.03±0.008 0.04±0.02 0.009 0.034 2 - 1; 3 - 1 
28 
15-hydroxy-eicosatrienoic acid 
15-HETrE DGLA LOX 0.003±0.004 
0.009±0.00
8 
0.006±0.003 0.014 0.047 
2 - 1; 3 - 1 
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29 6-keto-Prostaglandin E1 6kPGE1 DGLA COX 0.05±0.01 0.08±0.02 0.16±0.08 <0.001 0.003 2 - 1; 3 - 1; 3 - 2 
30 
Thromboxane B1 
TXB1 DGLA COX 0.02±0.006 
0.014±0.00
3 
0.11±0.04 <0.001 
<0.00
1 3 - 1; 3 - 2 
31 
10(S),17(S)-dihydroxy-
docosahexanoic acid 
10(S),17(S)-
DiHDoHE 
DHA LOX 11.2±13.9 27.5±8.8 35.6±16.8 0.004 0.017 
2 - 1; 3 - 1 
32 Protectin D1 PD1 dha LOX 11.2±7.4 13.6±11.2 33.9±13.5 0.004 0.019 3 - 1; 3 - 2 
33 
19, (20)-dihydroxy-docosapentenoic 
acid 
19,20-
DiHDPA 
DPA P450 0.009±0.006 0.03±0.02 0.02±0.009 0.007 0.028 
2 - 1; 3 - 1 
34 Eicosapentaenoic acid EPA EPA PUFA 19.1±18.3 42.4±24.5 49.5±7.79 0.011 0.038 2 - 1; 3 - 1 
35 
Prostaglandin F3α 
PGF3α EPA COX 
73809.3±350
94.1 
18830.7±1
5639.5 
22977.5±1012
8.6 
0.001 0.007 
1 - 2; 1 - 3 
36 Thromboxane B3 TXB3 EPA COX 0.05±0.01 0.03±0.01 0.09±0.09 <0.001 0.002 1 - 2; 3 - 1; 3 - 2 
37 Prostaglandin D3 PGD3 EPA COX 0.71±0.26 0.26±0.18 0.35±0.18 0.010 0.035 1-2; 
38 
Prostaglandin E3 
PGE3 EPA COX 0.18±0.09 3.63±1.95 1.51±0.35 <0.001 
<0.00
1 2 - 1; 3 - 1; 2 - 3 
39 9-oxo-octadecadienoic acid 9-oxoODE LA NE 2.39±1.06 6.2±2.1 7.9±2.8 <0.001 0.002 2 - 1; 3 - 1 
40 
5-hydroxy-eicosatrienoic acid 
5-HETrE Mead P450  
0.0009±0.00
09 
0.002±0.00
09 
0.003±0.0009 0.002 0.013 
2 - 1; 3 - 1 
   
          
ARTERY(pmol/ml)                   
  NAME ACRONYM PARENT MECH STD HFD HFD+AICAR p.value FDR Fisher's LSD 
1 
Arachidonic acid 
AA AA PUFA 
8771.31±193
0.89 
14906.19±
2726.51 
14113.42±275
5.44 
0.001 0.008 
2 - 1; 3 - 1 
2 
5-hydroxy-eicosapentaenoic acid 
5-HEPE AA LOX 2.53±0.28 0.38±0.13 0.29±0.10 <0.001 
<0.00
1 1 - 2; 1 - 3 
3 
12,13-epoxy-octadecenoic acid 
12,13-
EpOME 
AA P450  12.65±3.65 5.52±2.11 8.81±2.69 0.005 0.019 
1 - 2; 3 - 2 
4 
12,13-dihydroxy-octadecenoic 
acid 
12,13-
diHOME 
AA P450 38.65±13.16 10.86±6.82 45.12±27.10 0.001 0.005 
1 - 2; 3 - 2 
5 8,9-epoxy-eicosatrienoic acid 8,9-EET AA P450 0.10±0.14 3.77±3.41 1.08±0.87 0.002 0.012 2 - 1; 3 - 1 
6 
9,10-dihydroxy-octadecaenoic 
acid 
9,10-diHOME AA P450 16.71±6.03 7.38±4.10 26.75±12.49 0.002 0.008 
1 - 2; 3 - 2 
7 13-hydroxy-octadecaenoic acid 13-HODE ALA LOX 61.13±20.15 23.91±8.93 38.27±15.92 0.014 0.046 1-2; 
AMPK ameliorates eicosanoids in HFD induced-CKD                                       Declèves et al. 
 
 
5 
 
8 10-hydroxy-docosahexanoic acid 10-HDoHE DHA NE 2.56±0.92 1.05±0.51 1.49±0.41 0.007 0.027 1-2; 
9 13-hydroxy-docosahexanoic acid 13-HDoHE DHA NE 3.62±0.27 1.94±0.81 2.13±0.74 0.014 0.046 1 - 2; 1 - 3 
10 20-hydroxy-docosahexanoic acid 20-HDoHE DHA NE 1.48±0.62 0.11±0.10 0.07±0.15 <0.001 0.003 1 - 2; 1 - 3 
11 
4-hydroxy-docosahexanoic acid 
4-HDoHE DHA LOX 8.93±1.43 3.45±0.91 3.37±0.91 <0.001 
<0.00
1 1 - 2; 1 - 3 
12 16-hydroxy-docosahexanoic acid 16-HDoHE DHA P450 1.49±0.55 0.58±0.17 0.82±0.28 0.003 0.014 1 - 2; 1 - 3 
13 
Eicosapentaenoic acid 
EPA EPA PUFA 
12331.95±43
77.10 
4870.59±1
329.75 
3910.81±956.
15 
<0.001 0.003 
1 - 2; 1 - 3 
14 
18-hydroxy-eicosapentaenoic acid 
18-HEPE EPA NE 1.51±0.26 0.19±0.11 0.16±0.05 <0.001 
<0.00
1 1 - 2; 1 - 3 
15 9-hydroxy-eicosapentaenoic acid 9-HEPE EPA NE 3.56±1.84 0.11±0.13 0.11±0.15 0.001 0.005 1 - 2; 1 - 3 
16 12-hydroxy-eicosapentaenoic acid 12-HEPE EPA LOX 33.76±22.64 4.46±3.22 6.02±3.17 0.003 0.012 1 - 2; 1 - 3 
17 15-hydroxy-eicosapentaenoic acid 15-HEPE EPA LOX 1.65±0.46 0.20±0.13 0.03±0.05 <0.001 0.003 1 - 2; 1 - 3; 2 - 3 
18 14, (15)-epoxyeicosatetraenoic acid 14,15-EpETE EPA P450 0.56±0.18 0.18±0.05 0.11±0.10 <0.001 0.001 1 - 2; 1 - 3; 2 - 3 
19 
11-hydroxy-eicosapentaenoic acid 
11-HEPE EPA COX 1.45±0.18 0.18±0.07 0.16±0.07 <0.001 
<0.00
1 1 - 2; 1 - 3 
20 9-hydroxy-octatrienoic acid 9-HOTrE LA LOX 2.97±0.90 0.99±0.31 1.68±1.17 0.004 0.016 1 - 2; 1 - 3 
   
          
VEIN (pmol/ml)                   
  NAME ACRONYM PARENT MECH STD HFD HFD+AICAR p.value FDR Fisher's LSD 
1 
Arachidonic acid 
AA AA PUFA 
7763.61±111
0.50 
13307.28±
2881.09 
13715.20±388
8.78 
0.002 0.013 
2 - 1; 3 - 1 
2 
5-hydroxy-eicosapentaenoic acid 
5-HEPE AA LOX 2.26±0.64 0.17±0.11 0.29±0.09 <0.001 
<0.00
1 1 - 2; 1 - 3; 3 - 2 
3 11,12-epoxy-eicosatrienoic acid 11,12-EET AA P450 1.82±0.65 3.89±0.98 2.95±0.34 0.001 0.009 2 - 1; 3 - 1 
4 5, 6-epoxy-eicosatetraenoic acid 5, 6-EET AA P450 8.26±4.66 20.49±6.51 15.55±2.33 0.002 0.015 2 - 1; 3 - 1 
5 
4-hydroxy-docosahexanoic acid 
4-HDoHE DHA LOX 9.87±2.09 3.26±0.61 3.18±0.86 <0.001 
<0.00
1 1 - 2; 1 - 3 
6 7-hydroxy-docosahexanoic acid 7-HDoHE DHA LOX 0.91±0.38 0.34±0.42 0.05±0.08 0.008 0.041 1-3; 
7 
Eicosapentaenoic acid 
EPA EPA PUFA 
10459.89±41
75.56 
4259.23±1
425.09 
3679.71±840.
96 
0.001 0.011 
1 - 2; 1 - 3 
8 
18-hydroxy-eicosapentaenoic acid 
18-HEPE EPA NE 1.11±0.22 0.14±0.06 0.11±0.07 <0.001 
<0.00
1 1 - 2; 1 - 3 
9 15-hydroxy-eicosapentaenoic acid 15-HEPE EPA LOX 1.36±0.74 0.07±0.10 0.06±0.10 0.001 0.011 1 - 2; 1 - 3 
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10 
14, (15)-epoxy-eicosatetraenoic 
acid 
14,15-EpETE EPA P450 0.72±0.23 0.18±0.09 0.12±0.05 <0.001 
<0.00
1 1 - 2; 1 - 3 
11 11-hydroxy-eicosapentaenoic acid 11-HEPE EPA COX 1.06±0.22 0.21±0.10 0.11±0.13 0.003 0.017 1 - 3; 2 - 3 
12 9-hydroxy-octatrienoic acid 9-HOTrE LA LOX 1.87±0.68 0.69±0.21 1.33±0.57 0.002 0.013 1 - 2; 3 - 2 
                      
 
 
MECH- mechanism; STD – standard diet; HFD- high fat diet; HFD +AICAR – HFD with AICAR therapy; PUFA – polyunsaturated fatty acid; COX –cyclooxygenase; LOX 
–lipoxygenase; CYT-cytochrome P450 oxidase; NE- non-enzymatic degradation. P value for two way ANOVA; FDR- False discovery rate; Fisher’s LSD indicates posthoc 
tests comparing –STD (1),HFD(2), and HFD-AICAR(3) groups and represents only the significant comparisons. 
